EP1751105A1 - Piperazine derivatives of alkyl oxindoles - Google Patents
Piperazine derivatives of alkyl oxindolesInfo
- Publication number
- EP1751105A1 EP1751105A1 EP05745440A EP05745440A EP1751105A1 EP 1751105 A1 EP1751105 A1 EP 1751105A1 EP 05745440 A EP05745440 A EP 05745440A EP 05745440 A EP05745440 A EP 05745440A EP 1751105 A1 EP1751105 A1 EP 1751105A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- indol
- alkyl
- acid addition
- general formula
- carbon atom
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000004885 piperazines Chemical class 0.000 title description 2
- 150000005623 oxindoles Chemical class 0.000 title 1
- 229940066771 systemic antihistamines piperazine derivative Drugs 0.000 title 1
- 238000011282 treatment Methods 0.000 claims abstract description 20
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 19
- 238000011321 prophylaxis Methods 0.000 claims abstract description 8
- 208000035475 disorder Diseases 0.000 claims abstract description 7
- 150000001875 compounds Chemical class 0.000 claims description 64
- 150000003839 salts Chemical class 0.000 claims description 35
- 238000000034 method Methods 0.000 claims description 34
- 239000002253 acid Substances 0.000 claims description 31
- 229910052799 carbon Inorganic materials 0.000 claims description 31
- 229910052736 halogen Inorganic materials 0.000 claims description 28
- 150000002367 halogens Chemical class 0.000 claims description 28
- 125000003545 alkoxy group Chemical group 0.000 claims description 27
- 229910052739 hydrogen Inorganic materials 0.000 claims description 24
- 239000001257 hydrogen Substances 0.000 claims description 24
- 125000000217 alkyl group Chemical group 0.000 claims description 23
- -1 ethylene-dioxy Chemical group 0.000 claims description 21
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 17
- 239000008194 pharmaceutical composition Substances 0.000 claims description 15
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 12
- 210000003169 central nervous system Anatomy 0.000 claims description 10
- 208000024172 Cardiovascular disease Diseases 0.000 claims description 9
- 238000002360 preparation method Methods 0.000 claims description 8
- 201000010099 disease Diseases 0.000 claims description 7
- RUZLIIJDZBWWSA-INIZCTEOSA-N methyl 2-[[(1s)-1-(7-methyl-2-morpholin-4-yl-4-oxopyrido[1,2-a]pyrimidin-9-yl)ethyl]amino]benzoate Chemical compound COC(=O)C1=CC=CC=C1N[C@@H](C)C1=CC(C)=CN2C(=O)C=C(N3CCOCC3)N=C12 RUZLIIJDZBWWSA-INIZCTEOSA-N 0.000 claims description 7
- 208000024827 Alzheimer disease Diseases 0.000 claims description 6
- 208000018522 Gastrointestinal disease Diseases 0.000 claims description 6
- 239000004480 active ingredient Substances 0.000 claims description 6
- 239000012752 auxiliary agent Substances 0.000 claims description 6
- 239000000460 chlorine Substances 0.000 claims description 6
- 230000003340 mental effect Effects 0.000 claims description 6
- 239000000203 mixture Substances 0.000 claims description 6
- 201000000980 schizophrenia Diseases 0.000 claims description 6
- 208000008811 Agoraphobia Diseases 0.000 claims description 5
- 208000019901 Anxiety disease Diseases 0.000 claims description 5
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims description 5
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims description 5
- 208000011688 Generalised anxiety disease Diseases 0.000 claims description 5
- 206010020772 Hypertension Diseases 0.000 claims description 5
- 201000001880 Sexual dysfunction Diseases 0.000 claims description 5
- 206010041250 Social phobia Diseases 0.000 claims description 5
- 208000013200 Stress disease Diseases 0.000 claims description 5
- 230000036506 anxiety Effects 0.000 claims description 5
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims description 5
- 229910052794 bromium Inorganic materials 0.000 claims description 5
- 229910052801 chlorine Inorganic materials 0.000 claims description 5
- 208000010877 cognitive disease Diseases 0.000 claims description 5
- 230000007423 decrease Effects 0.000 claims description 5
- 239000003814 drug Substances 0.000 claims description 5
- 208000029364 generalized anxiety disease Diseases 0.000 claims description 5
- 229910052757 nitrogen Inorganic materials 0.000 claims description 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 5
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims description 5
- 208000019906 panic disease Diseases 0.000 claims description 5
- 208000019899 phobic disease Diseases 0.000 claims description 5
- 208000028173 post-traumatic stress disease Diseases 0.000 claims description 5
- 231100000872 sexual dysfunction Toxicity 0.000 claims description 5
- 208000011580 syndromic disease Diseases 0.000 claims description 5
- 206010012289 Dementia Diseases 0.000 claims description 4
- 208000012545 Psychophysiologic disease Diseases 0.000 claims description 4
- 208000006011 Stroke Diseases 0.000 claims description 4
- 125000005278 alkyl sulfonyloxy group Chemical group 0.000 claims description 4
- 208000015114 central nervous system disease Diseases 0.000 claims description 4
- 239000011230 binding agent Substances 0.000 claims description 3
- QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 claims description 3
- 150000007522 mineralic acids Chemical class 0.000 claims description 3
- 230000004770 neurodegeneration Effects 0.000 claims description 3
- 150000007524 organic acids Chemical class 0.000 claims description 3
- JYGFTBXVXVMTGB-UHFFFAOYSA-N Oxindol Natural products C1=CC=C2NC(=O)CC2=C1 JYGFTBXVXVMTGB-UHFFFAOYSA-N 0.000 claims description 2
- 239000012050 conventional carrier Substances 0.000 claims description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 2
- 150000007530 organic bases Chemical class 0.000 claims description 2
- 150000001721 carbon Chemical group 0.000 claims 13
- 150000002431 hydrogen Chemical class 0.000 claims 7
- 208000026139 Memory disease Diseases 0.000 claims 3
- 206010057248 Cell death Diseases 0.000 claims 1
- 125000003118 aryl group Chemical group 0.000 claims 1
- 230000002490 cerebral effect Effects 0.000 claims 1
- 230000009089 cytolysis Effects 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 150000003222 pyridines Chemical class 0.000 claims 1
- 150000005625 indol-2-ones Chemical class 0.000 abstract description 7
- 210000000748 cardiovascular system Anatomy 0.000 abstract description 2
- 230000002349 favourable effect Effects 0.000 abstract description 2
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 21
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 18
- 125000004432 carbon atom Chemical group C* 0.000 description 18
- 102000005962 receptors Human genes 0.000 description 14
- 108020003175 receptors Proteins 0.000 description 14
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 12
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 12
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 11
- 230000000694 effects Effects 0.000 description 10
- 238000003672 processing method Methods 0.000 description 10
- 239000000243 solution Substances 0.000 description 9
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 8
- 238000004458 analytical method Methods 0.000 description 8
- 230000027455 binding Effects 0.000 description 7
- 238000009739 binding Methods 0.000 description 7
- OAYLNYINCPYISS-UHFFFAOYSA-N ethyl acetate;hexane Chemical compound CCCCCC.CCOC(C)=O OAYLNYINCPYISS-UHFFFAOYSA-N 0.000 description 7
- 238000005160 1H NMR spectroscopy Methods 0.000 description 6
- 238000005481 NMR spectroscopy Methods 0.000 description 6
- 230000015572 biosynthetic process Effects 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 125000001424 substituent group Chemical group 0.000 description 5
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- 230000006978 adaptation Effects 0.000 description 4
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 4
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 239000002249 anxiolytic agent Substances 0.000 description 3
- 230000000949 anxiolytic effect Effects 0.000 description 3
- 239000000969 carrier Substances 0.000 description 3
- 239000003921 oil Substances 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 239000000829 suppository Substances 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- SVUOLADPCWQTTE-UHFFFAOYSA-N 1h-1,2-benzodiazepine Chemical compound N1N=CC=CC2=CC=CC=C12 SVUOLADPCWQTTE-UHFFFAOYSA-N 0.000 description 2
- WSZKTJZUGPVNFY-UHFFFAOYSA-N 3-(4-hydroxybutyl)-1,3-dihydroindol-2-one Chemical class C1=CC=C2C(CCCCO)C(=O)NC2=C1 WSZKTJZUGPVNFY-UHFFFAOYSA-N 0.000 description 2
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 2
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 2
- 239000001828 Gelatine Substances 0.000 description 2
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 208000035755 Psychosomatic disease Diseases 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 230000032683 aging Effects 0.000 description 2
- 125000005279 aryl sulfonyloxy group Chemical group 0.000 description 2
- 229940049706 benzodiazepine Drugs 0.000 description 2
- 239000006172 buffering agent Substances 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 125000000623 heterocyclic group Chemical group 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000000155 melt Substances 0.000 description 2
- 206010027175 memory impairment Diseases 0.000 description 2
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 description 2
- 230000009871 nonspecific binding Effects 0.000 description 2
- 239000012074 organic phase Substances 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 125000006239 protecting group Chemical group 0.000 description 2
- 208000020016 psychiatric disease Diseases 0.000 description 2
- 235000012239 silicon dioxide Nutrition 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- IOPLFBPKCMFORO-UHFFFAOYSA-N 3-(4-hydroxybutyl)-5-methyl-1,3-dihydroindol-2-one Chemical compound CC1=CC=C2NC(=O)C(CCCCO)C2=C1 IOPLFBPKCMFORO-UHFFFAOYSA-N 0.000 description 1
- AHJOSYULWRUECL-UHFFFAOYSA-N 3-[4-(4-pyridin-2-ylpiperazin-1-yl)butyl]-1,3-dihydroindol-2-one Chemical compound O=C1NC2=CC=CC=C2C1CCCCN(CC1)CCN1C1=CC=CC=N1 AHJOSYULWRUECL-UHFFFAOYSA-N 0.000 description 1
- NDERFKLSEAOZMY-UHFFFAOYSA-N 3-[4-[4-(3-methoxyphenyl)piperazin-1-yl]butyl]-1,3-dihydroindol-2-one;oxalic acid Chemical compound OC(=O)C(O)=O.COC1=CC=CC(N2CCN(CCCCC3C4=CC=CC=C4NC3=O)CC2)=C1 NDERFKLSEAOZMY-UHFFFAOYSA-N 0.000 description 1
- VPHQTVYHZFPMMW-UHFFFAOYSA-N 3-[4-[4-(5-chloro-2-methoxyphenyl)piperazin-1-yl]butyl]-1,3-dihydroindol-2-one Chemical compound COC1=CC=C(Cl)C=C1N1CCN(CCCCC2C3=CC=CC=C3NC2=O)CC1 VPHQTVYHZFPMMW-UHFFFAOYSA-N 0.000 description 1
- PLZHOPHPOVTDOV-UHFFFAOYSA-N 3-[4-[4-(5-chloro-2-methoxyphenyl)piperazin-1-yl]butyl]-1,3-dihydroindol-2-one;hydrochloride Chemical compound Cl.COC1=CC=C(Cl)C=C1N1CCN(CCCCC2C3=CC=CC=C3NC2=O)CC1 PLZHOPHPOVTDOV-UHFFFAOYSA-N 0.000 description 1
- XLVTXMNCZKRSKQ-UHFFFAOYSA-N 4-(5-methyl-2-oxo-1,3-dihydroindol-3-yl)butyl methanesulfonate Chemical compound CC1=CC=C2NC(=O)C(CCCCOS(C)(=O)=O)C2=C1 XLVTXMNCZKRSKQ-UHFFFAOYSA-N 0.000 description 1
- AJVMAKZWIVVRDR-UHFFFAOYSA-N 4-(6-fluoro-2-oxo-1,3-dihydroindol-3-yl)butyl methanesulfonate Chemical compound FC1=CC=C2C(CCCCOS(=O)(=O)C)C(=O)NC2=C1 AJVMAKZWIVVRDR-UHFFFAOYSA-N 0.000 description 1
- XVVMEILIWXETCU-UHFFFAOYSA-N 5-fluoro-3-[4-[4-(3-methoxyphenyl)piperazin-1-yl]butyl]-1,3-dihydroindol-2-one Chemical compound COC1=CC=CC(N2CCN(CCCCC3C4=CC(F)=CC=C4NC3=O)CC2)=C1 XVVMEILIWXETCU-UHFFFAOYSA-N 0.000 description 1
- NGESYJMKWBBETF-UHFFFAOYSA-N 5-fluoro-3-[4-[4-(3-methoxyphenyl)piperazin-1-yl]butyl]-1,3-dihydroindol-2-one;oxalic acid Chemical compound OC(=O)C(O)=O.COC1=CC=CC(N2CCN(CCCCC3C4=CC(F)=CC=C4NC3=O)CC2)=C1 NGESYJMKWBBETF-UHFFFAOYSA-N 0.000 description 1
- 108091032151 5-hydroxytryptamine receptor family Proteins 0.000 description 1
- SKAVNVWCLGFNBS-UHFFFAOYSA-N 6-fluoro-3-(4-hydroxybutyl)-1,3-dihydroindol-2-one Chemical compound FC1=CC=C2C(CCCCO)C(=O)NC2=C1 SKAVNVWCLGFNBS-UHFFFAOYSA-N 0.000 description 1
- NDEQQLAZHRZSEI-UHFFFAOYSA-N 6-fluoro-3-[4-(4-pyridin-2-ylpiperazin-1-yl)butyl]-1,3-dihydroindol-2-one Chemical compound O=C1NC2=CC(F)=CC=C2C1CCCCN(CC1)CCN1C1=CC=CC=N1 NDEQQLAZHRZSEI-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical group [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 206010010219 Compulsions Diseases 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 208000020401 Depressive disease Diseases 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- 102000014630 G protein-coupled serotonin receptor activity proteins Human genes 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical class CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- 239000012359 Methanesulfonyl chloride Substances 0.000 description 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
- NIPNSKYNPDTRPC-UHFFFAOYSA-N N-[2-oxo-2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 NIPNSKYNPDTRPC-UHFFFAOYSA-N 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 1
- 208000028017 Psychotic disease Diseases 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- 206010039966 Senile dementia Diseases 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
- 201000004810 Vascular dementia Diseases 0.000 description 1
- 230000001133 acceleration Effects 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000003276 anti-hypertensive effect Effects 0.000 description 1
- 230000000767 anti-ulcer Effects 0.000 description 1
- 239000000164 antipsychotic agent Substances 0.000 description 1
- 229940005530 anxiolytics Drugs 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- RBHJBMIOOPYDBQ-UHFFFAOYSA-N carbon dioxide;propan-2-one Chemical compound O=C=O.CC(C)=O RBHJBMIOOPYDBQ-UHFFFAOYSA-N 0.000 description 1
- 150000004649 carbonic acid derivatives Chemical class 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 239000007979 citrate buffer Substances 0.000 description 1
- QZUDBNBUXVUHMW-UHFFFAOYSA-N clozapine Chemical compound C1CN(C)CCN1C1=NC2=CC(Cl)=CC=C2NC2=CC=CC=C12 QZUDBNBUXVUHMW-UHFFFAOYSA-N 0.000 description 1
- 229960004170 clozapine Drugs 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 229960000913 crospovidone Drugs 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- WZHCOOQXZCIUNC-UHFFFAOYSA-N cyclandelate Chemical compound C1C(C)(C)CC(C)CC1OC(=O)C(O)C1=CC=CC=C1 WZHCOOQXZCIUNC-UHFFFAOYSA-N 0.000 description 1
- 229960003529 diazepam Drugs 0.000 description 1
- AAOVKJBEBIDNHE-UHFFFAOYSA-N diazepam Chemical compound N=1CC(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 AAOVKJBEBIDNHE-UHFFFAOYSA-N 0.000 description 1
- UZBQIPPOMKBLAS-UHFFFAOYSA-N diethylazanide Chemical compound CC[N-]CC UZBQIPPOMKBLAS-UHFFFAOYSA-N 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- DEQYTNZJHKPYEZ-UHFFFAOYSA-N ethyl acetate;heptane Chemical compound CCOC(C)=O.CCCCCCC DEQYTNZJHKPYEZ-UHFFFAOYSA-N 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 210000005153 frontal cortex Anatomy 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000001727 glucose Nutrition 0.000 description 1
- 125000005843 halogen group Chemical group 0.000 description 1
- 150000002430 hydrocarbons Chemical group 0.000 description 1
- 229910000042 hydrogen bromide Inorganic materials 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- QNLOWBMKUIXCOW-UHFFFAOYSA-N indol-2-one Chemical group C1=CC=CC2=NC(=O)C=C21 QNLOWBMKUIXCOW-UHFFFAOYSA-N 0.000 description 1
- 150000002475 indoles Chemical class 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 239000000644 isotonic solution Substances 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 239000003158 myorelaxant agent Substances 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 150000003891 oxalate salts Chemical class 0.000 description 1
- GEVPUGOOGXGPIO-UHFFFAOYSA-N oxalic acid;dihydrate Chemical compound O.O.OC(=O)C(O)=O GEVPUGOOGXGPIO-UHFFFAOYSA-N 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 229940021222 peritoneal dialysis isotonic solution Drugs 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 1
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- IENZQIKPVFGBNW-UHFFFAOYSA-N prazosin Chemical compound N=1C(N)=C2C=C(OC)C(OC)=CC2=NC=1N(CC1)CCN1C(=O)C1=CC=CO1 IENZQIKPVFGBNW-UHFFFAOYSA-N 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 235000019624 protein content Nutrition 0.000 description 1
- 239000002464 receptor antagonist Substances 0.000 description 1
- 229940044551 receptor antagonist Drugs 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 230000002040 relaxant effect Effects 0.000 description 1
- 238000009877 rendering Methods 0.000 description 1
- 229930195734 saturated hydrocarbon Natural products 0.000 description 1
- 150000003335 secondary amines Chemical class 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 230000001624 sedative effect Effects 0.000 description 1
- 210000000697 sensory organ Anatomy 0.000 description 1
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000000844 transformation Methods 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 229940086542 triethylamine Drugs 0.000 description 1
- ILWRPSCZWQJDMK-UHFFFAOYSA-N triethylazanium;chloride Chemical compound Cl.CCN(CC)CC ILWRPSCZWQJDMK-UHFFFAOYSA-N 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
- C07D209/32—Oxygen atoms
- C07D209/34—Oxygen atoms in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Definitions
- the invention relates to new, substituted indol-2-one derivatives and pharmaceutically acceptable acid addition salts thereof, furthermore to a process for the preparation of said compounds.
- the invention also encompasses pharmaceutical compositions containing said new indol-2-one derivatives and the use of said compounds for the treatment of diseases.
- R 1 and R 2 independently represent hydrogen, halogen, alkyl or alkoxy having 1-7 carbon atom(s) or trifluoromethyl
- R 3 is hydrogen
- - Q represents nitrogen
- R 4 and R 5 independently represent hydrogen, halogen, trifluoromethyl, straight or branched chain alkyl or alkoxy having 1 to 7 carbon atom(s)
- R 6 denotes hydrogen, halogen, alkyl or alkoxy having 1 to 7 carbon atom(s), or R 4 and R 5 together form ethylenedioxy
- Q is a CH group and R 4 and R 5 together form ethylenedioxy
- R 6 stands for halogen or alkoxy having 1 to 7 carbon atom(s), or Q is a CH group and R 4 , R 5 and R 6 independently represent alkyl or alkoxy having 1 to 7 carbon atom(s) or halogen
- m is 1, 2, 3 or 4, and.pharmaceutically acceptable acid addition salts thereof.
- U.S. patent No. 4,452,808 discloses 4-aminoalkyl indol-2-one derivatives having a selective D 2 receptor activity. These compounds can be used for the treatment of hypertension.
- One of the compounds provided by said patent namely 4-[2-(di-N- propylamino)ethyl]-2(3H)-indolone, is used for the clinical treatment of Parkinson disease.
- European patent No. 281,309 provides indol-2-one derivatives carrying an arylpiperazinyl-alkyl substituent in position 5, which can be applied for the treatment of psychotic conditions.
- One of the compounds described in said patent namely 5-[2-[4-(l,2- benzisothiazol-3-yl)-l-piperazinyl]-ethyl]-6-chloro-l,3-dihydro- 2H-indol-2-one, exerts its activity by interaction with D 2 , 5-HT] A and 5-HT 2 receptors and is used in the clinical treatment as an antipsychotic agent.
- European patent No. 376,607 discloses indol-2-one derivatives substituted in position 3 by an alkylpiperazinyl-aryl group, which exert their activity on 5-HT ⁇ A receptor and are useful for the treatment of central nervous disorders.
- indol-2- one derivatives containing a substituted alkyl-piperazinyl, substituted alkyl-piperidinyl or alkyl-cyclohexyl group in position 3 are disclosed. These compounds possess psychotrophic activity. Said patent specification is completely silent in mentioning anything about the activity profile of the said compounds, and as a field of application only the treatment of depression and anxiety are mentioned.
- the acceleration of technical-social development in the twentieth century constitutes a permanent compulsion of adaptation for humans, which, in adverse cases, may lead to the occurrence of adaptation disorders.
- Adaptation disorders constitute an important risk factor in the development of diseases of mental or psycho-somatic origin, such as anxiolytic syndrome, stress disorder, depression, schizophrenia, disorders of the sense organs, gastrointestinal diseases, cardiovascular diseases and disorders of the secretory organs.
- Anxiolytics of benzodiazepine type are accompanied, however, by several unpleasant side-effects. They have a strong sedative activity, cause decline of the power of concentration and memory and possess muscle relaxant effect. Said side-effects influence the quality of life of the patients in an adverse manner and thus restrict the scope of application of such pharmaceuticals.
- the object of the present invention is to develop pharmaceutical ingredients having more favourable activity profile than those applied for the time being, which are devoid of the above- specified drawbacks and undesired side-effects and which, at the same time, can be used for the treatment and prophylaxis of disorders of the central nervous and cardiovascular system.
- the invention is based on the surprising recognition that the substituted indol-2-one derivatives of the general Formula (I) - in contrast to the prior art compounds of similar structure - show a considerable binding to both 5-HT and a. ⁇ receptors. Accordingly, it can be expected that their applicability will encompass the treatment of both central nervous and cardiovascular disorders.
- R 1 and R 2 independently represent hydrogen, halogen, alkyl or alkoxy having 1-7 carbon atom(s) or trifluoromethyl,
- R 3 is hydrogen
- R 4 and R 5 independently represent hydrogen, halogen, trifluoromethyl, straight or branched chain alkyl or alkoxy having 1 to 7 carbon atom(s),
- R 6 denotes hydrogen, halogen, alkyl or alkoxy having 1 to 7 carbon atom(s), or
- R 4 and R 5 together form ethylenedioxy
- Q is a CH group and R 4 and R 5 together form ethylenedioxy, and R 6 stands for halogen or alkoxy having 1 to 7 carbon atom(s), or
- Q is a CH group and R 4 , R 5 and R 6 independently represent alkyl or alkoxy having 1 to 7 carbon atom(s) or halogen;
- n 1, 2, 3 or 4
- ком ⁇ онент used throughout this specification is intended to mean straight or branched chain saturated hydrocarbon groups having 1 to 7, preferably 1 to 4 carbon atom(s), (e.g. methyl, ethyl, 1-propyl, 2-propyl, n-butyl, isobutyl or tert. butyl group etc.)
- the term facedhalogen encompasses the fluorine, chlorine, bromine and iodine atoms and is preferably chlorine or bromine.
- the leaving group can be an alkylsulfonyloxy or arylsulfonyloxy group, e.g. methylsulfonyloxy (mesyloxy) or p- toluenesulfonyloxy group; or a halogen atom, preferably bromine or chlorine.
- pharmaceutically acceptable acid addition salts relates to non-toxic salts of the compounds of the general Formula (I) formed with pharmaceutically acceptable organic or inorganic acids.
- Inorganic acids suitable for salt formation are e.g. hydrogen chloride, hydrogen bromide, phosphoric, sulfuric or nitric acid.
- organic acids formic, acetic, propionic, maleic, fumaric, succinic, lactic, malic, tartaric, citric, ascorbic, malonic, oxalic, mandelic, glycolic, phtalic, benzenesulfonic, p-toluene- sulfonic, naphthalic or methanesulfonic acids can be used.
- carbonates and hydrocarbonates are also considered as pharmaceutically acceptable salts.
- R and R independently represent hydrogen, halogen, alkyl or alkoxy having 1 to 7 carbon atom(s) or trifluoromethyl;
- R 3 is hydrogen
- R 4 and R 5 independently represent hydrogen, halogen, trifluoromethyl or straight or branched chain alkyl or alkoxy having 1 to 7 carbon atom(s),
- R 6 is hydrogen, halogen, alkyl or alkoxy having 1 to 7 carbon atom(s), or
- R 4 and R 5 together form ethylenedioxy; m is 1, 2, 3 or 4; and pharmaceutically acceptable acid addition salts thereof.
- R 1 and R 2 independently represent hydrogen, halogen, alkyl or alkoxy having 1 to 7 carbon atom(s) or trifluoromethyl,
- R is hydrogen
- Q is a CH group and R 4 and R 5 together form ethylenedioxy, R 6 denotes halogen or alkoxy having 1 to 7 carbon atom(s), or
- Q is a CH group and R 4 , R 5 and R 6 independently represent halogen or alkyl or alkoxy having 1 to 7 carbon atom(s), m is 1, 2, 3 or 4; and pharmaceutically acceptable acid addition salts thereof.
- Particularly preferable representatives of the compounds of general Formula (I) are the following derivatives: 3- ⁇ 4-[4-(7-chloro-2,3-dihydrobenzo[l,4]dioxin-5-yl)-piperazine- 1 -yl]-butyl ⁇ -5-fluoro- 1 ,3 -dihydro-2H-indol-2-one, 3- ⁇ 4-[4-(5-chloro-2-methoxyphenyl)-piperazine- 1 -yl]-butyl ⁇ - 1 ,3- dihydro-2H-indol-2-one,
- L is hydroxy, with an arylsulfonyl chloride or a straight or branched chain alkylsulfonyl chloride having 1 to 7 carbon atom(s), preferably methylsulfonyl chloride, in the presence of an organic base, and reacting the thus- obtained compound of the general Formula (II), wherein L is aryl- or alkylsulfonyloxy, with a piperazine derivative of the general Formula (III) in the presence of an acid binding agent, or
- R 4 , R 5 , R 6 is as defined above, m is 1, 2, 3 or 4, L is a leaving group, preferably chlorine or bromine, in the presence of a strong base.
- the compounds of the general Formula (I), wherein R ! -R 6 , m and Q are as stated above, can be prepared by reacting a compound of the general Formula (II), wherein R !
- L is a leaving group, preferably alkyl- sulfonyloxy, most preferably methylsulfonyloxy, with a compound of the general Formula (III), wherein R 4 -R 6 and Q are as stated above, according to methods known from the literature [Houben-Weyl: Methoden der organischen Chemie, Georg Thieme Verlag, Stuttgart, 1992, 4 th Edition, vol. E16d (ed.: D. Klamann); R. C. Larock: Comprehensive Organic Transformations, 2. kiadas, John Wiley & Sons, New York, 1999, 789; D. A. Walsh, Y-H. Chen, J. B. Green, J. C. Nolan, J. M. Yanni J Med. Chem. 1990, 33, 1823-1827].
- the compounds of the general Formula (I), wherein R'-R 6 and m are as stated above, can also be prepared by reacting a compound of the general Formula (V), wherein R ! -R 3 are as stated above, with a compound of the general Formula (VI), wherein R 4 -R 6 , m and Q are as stated above and L is a leaving group, by methods known from the literature [R. J. Sundberg: The chemistry of indoles, Academic Press, New York, 1970, vol. VII. ; A. R. Katritzky, Ch. W. Rees: Comprehensive Heterocyclic Chemistry, 1 th Edition, Pergamon, Oxford, 1984, vol. 4. (ed.: C. W. Bird, G. W. H.
- the compounds of the general Formula (I), wherein R'-R 6 , m and Q are as stated above, can also be prepared by carrying out the formation of the substituents R'-R in different succession in the last reaction step.
- a compound of the general Formula (I) is used as starting substance wherein all substituents are as stated above except the one to be formed, which can be any one selected from R 1 , R 2 , R 3 , R 4 , R 5 and R 6
- the introduction and conversion of the substituents are carried out according to methods known from the literature [Houben-Weyl: Methoden der organischen Chemie, Georg Thieme Verlag, Stuttgart, 1977, 4 th Edition, TvVla-d; V/2b k ⁇ tet].
- the compounds of the general Formulae (III), (IV), (V) and (VI) are known from the literature or can be produced by analogous methods.
- the compounds of the general Formula (I) can be set free from their salts or converted into pharmaceutically acceptable acid addition salts according to methods known from the literature.
- compositions comprising as active ingredient a compound of the general Formula (I) or a pharmaceutically acceptable acid addition salt thereof in admixture with one or more conventional carrier(s) or auxiliary agent(s).
- compositions according to the present invention contain generally 0,1-95 % by weight, preferably 1-50 % by weight, particularly 5-30 % by weight of the active ingredient.
- compositions of the present invention may be suitable for oral (e.g. powders, tablets, coated tablets, capsules, microcapsules, pills, solutions, suspensions or emulsions), parenteral (e.g. injection solutions for intravenous, intramuscular, subcutaneous or intraperitoneal use), rectal (e.g. suppositories) transdermal (e.g. plasters) or local (e.g. ointments or plasters) administration or for the application in form of implants.
- parenteral e.g. injection solutions for intravenous, intramuscular, subcutaneous or intraperitoneal use
- rectal e.g. suppositories
- transdermal e.g. plasters
- local e.g. ointments or plasters
- the solid, soft or liquid pharmaceutical compositions according to the invention may be produced by methods conventionally applied in the pharmaceutical industry.
- the solid pharmaceutical compositions for oral administration containing the compounds of the general Formula (I) or pharmaceutically acceptable acid addition salts thereof may comprise fillers or carriers (such as lactose, glucose, starch, calcium phosphate, micro-crystalline cellulose), binding agents (such as gelatine, sorbite, polyvinyl py ⁇ olidone), disintegrants (such as croscarmelose, Na-carboxymethyl cellulose, crospovidone), tabletting auxiliary agents (such as magnesium stearate, talc, polyethylene glycol, silicic acid, silicon dioxide) and surface-active agents (e.g. sodium lauryl sulfate).
- fillers or carriers such as lactose, glucose, starch, calcium phosphate, micro-crystalline cellulose
- binding agents such as gelatine, sorbite, polyvinyl py ⁇ olidone
- disintegrants such as croscarmelose, Na-carboxymethyl cellulose, crospovidone
- tabletting auxiliary agents such as
- compositions suitable for oral administration can be solutions, suspensions or emulsions.
- Such compositions may contain suspending agents (e.g. gelatine, carboxymethyl cellulose), emulsifiers (e.g. sorbitane monooleate, solvents (e.g. water, oils, glycerol, propylene glycol, ethanol), buffering agents (e.g. acetate, phosphate, citrate buffers) and preservatives (e.g. methyl-4-hydroxyb enzoate) .
- suspending agents e.g. gelatine, carboxymethyl cellulose
- emulsifiers e.g. sorbitane monooleate
- solvents e.g. water, oils, glycerol, propylene glycol, ethanol
- buffering agents e.g. acetate, phosphate, citrate buffers
- preservatives e.g. methyl-4-hydroxyb enzoate
- Liquid pharmaceutical compositions suitable for parenteral administration are generally sterile isotonic solutions optionally containing, in addition to the solvent, buffering agents and preservatives.
- Soft pharmaceutical compositions containing as active ingredient a compound of the general Formula (I) or a pharmaceutically acceptable acid addition salt thereof, such as suppositories contain the active ingredient evenly dispersed in the basic material of the suppository (e.g. in polyethylene glycol or cocoa butter).
- compositions suitable for the treatment or prophylaxis of central nervous disorders or psychosomatic diseases particularly generalized anxiety disorders, panic disease, compulsive disorder, social phobia, agoraphobia, phobias in connection with specific situations, post-traumatic stress disorders, post-traumatic memory disturbances, cognitive disorders, sexual dysfunction of central nervous system origin, depression, schizophrenia; gastrointestinal diseases and cardiovascular diseases.
- the pharmaceutical compositions according to the present invention can be prepared by known methods of the pharmaceutical industry.
- the active ingredient is admixed with pharmaceutically acceptable solid or liquid carriers and/or auxiliary agents and the mixture is brought to galenic form.
- pharmaceutically acceptable solid or liquid carriers and/or auxiliary agents together with the methods which can be used in the pharmaceutical industry are disclosed in the literature (Remington's Pharmaceutical Sciences, Edition 18, Mack Publishing Co., Easton, USA, 1990).
- the pharmaceutical compositions according to the present invention contain generally a dosage unit.
- the daily dosage for human adults can be generally 0,1-1000 mg/kg body weight of a compound of the general Formula (I) or a pharmaceutically acceptable acid addition salts thereof. Said daily dose can be administered in one or more portion(s). The actual daily dose depends on several factors and is determined by the physician.
- anxiety syndrome particularly generalized anxiety disorders, panic disease, compulsive disorder, social phobia, agoraphobia, phobias in connection with specific situations, stress disorders, post- traumatic stress disorders, post-traumatic memory disturbances, cognitive disorders, sexual dysfunction of central nervous system origin, depression, schizophrenia, neurodegeneration followed by mental decline, Alzheimer's disease, stroke, dementias, furthermore gastrointestinal diseases and cardiovascular diseases, particularly hypertension.
- the invention is based on the surprising recognition that the 3- alkyl-indol-2-one derivatives of the general Formula (I) - in contrast to the prior art compounds of similar structure - show a considerable binding to both 5-HT 7 , and ci] receptors.
- 5-HT receptor affinity human cloned receptors were used.
- the receptor affinities were determined from isolated frontal cortex preparation of male Wistar rats weighing 120-200 g.
- the protein contents of membrane preparations were determined by the method of Lowry (1951).
- the ligands were 3 H-lizergic acid diethylamide (LSD) (1.0 nM) and 3 H- prazosine (0.3 nM). Clozapine (25 ⁇ M) and prazosine (1 ⁇ M) were used for the measurement of non-specific bindings.
- the ⁇ i receptor binding studies were carried out according to the methods of Reader, and Greengrass (Reader, T.A., Briere, R., Grondin, L.: J. Neural Transm. 68, p. 79 (1987); Greengrass, P., Brenner, R.: Eur. J. Pharmacol. 55, p. 323 (1979) ).
- IC 50 is the concentration where the difference between the whole binding and non-specific binding is 50%.
- the compounds with an IC 50 value smaller than 100 nmol were considered effective in this test.
- the results of the experiments are presented in Tables 2 and 3.
- the title compound is prepared according to process A starting from 5-fluoro-3-(4-hydroxybutyl)-l ,3-dihydro-2H-indol-2-one. M.p.: 106-108 °C (hexane-ethyl acetate).
- the title compound is prepared according to process A starting from 6-fluoro-3-(4-hydroxybutyl)- 1 ,3-dihydro-2H-indol-2-one. M.p.: 106-108 °C (hexane-ethyl acetate). IR (KBr): 3161, 1705 (CO), 1335, 1313, 1167 (SO 2 ) cm "1 .
- the title compound is prepared according to process A starting from 3-(4-hydroxybutyl)-5-methyl- 1 ,3-dihydro-2H-indol-2-one. M.p.: 89-90 °C (hexane-ethyl acetate).
- the melt of the secondary amine (12 mmoles) is warmed to 120 °C under slow stirring, and the mesyl compound (12 mmoles) and sodium carbonate (1.36 g; 12 mmoles) are added to it at the same temperature.
- the mixture is allowed to react for 1 hour, the melt is allowed to cool, ethyl acetate and water are added to it and the phases are separated.
- the organic phase is evaporated, the residual oil is subjected to chromatography on a short column using ethyl acetate as eluent. As main products the desired compounds are obtained.
- Processing method 1 If the product purified by column chromatography gets crystalline upon rubbing with diethyl ether, it is filtered off and recrystallized from a mixture of hexane and ethyl acetate. The desired compounds are obtained in form of white crystals.
- Processing method 2 If the basic product does not get crystalline upon the addition of diethyl ether, it is dissolved in 200 ml of ether, the slight amount of floating precipitate is filtered off and to the pure solution the calculated amount (1 molar equivalent) of hydrogen chloride dissolved in ether diluted with 50 ml of diethyl ether is dropped under vigorous stirring.
- the separated white salt is filtered off, washed with ether and hexane and dried in a vacuum pistol at room temperature for 3 hours.
- Processing method 3 If the basic product does not get crystalline upon the addition of diethyl ether and does not provide a well- filterable salt with hydrogen chloride, it is dissolved in 100 ml of hot ethyl acetate, and a solution of 1 molar equivalent of oxalic acid dihydrate in 30 ml of hot ethyl acetate is dropped to it within 10 minutes, under stirring. The white oxalate salt gets separated upon cooling. It is filtered off at room temperature, washed with ethyl acetate and hexane and dried.
- the title compound is prepared according to process B by applying processing method 1 starting from 3-(4-mesyloxybutyl)- l,3-dihydro-2H-indol-2-one and l-(pyridin-2-yl)-piperazine. M.p.: 131-132 °C (hexane-ethyl acetate).
- the title compound is prepared according to process B by applying processing method 3 starting from 3-(4-mesyloxybutyl)- l,3-dihydro-2H-indol-2-one and l-(7-chloro-2,3-dihydrobenzo- [l,4]dioxin-5-yl)-piperazine. M.p.: 236-238 °C.
- the title compound is prepared according to process B/1 starting from 5-fluoro-3-(4-mesyl-oxybutyl)-l ,3-dihydro-2H-indol-2-one and l-(pyridin-2-yl)-piperazine. M.p.: 132-134 °C (hexane-ethyl acetate).
- the title compound is prepared according to process B by applying processing method 1 starting from 6-fluoro-3-(4- mesyloxybutyl)-l,3-dihydro-2H-indol-2-one and l-(pyridin-2- yl)-piperazine.
- the title compound is prepared according to process B by applying processing method 3 starting from 3-(4-mesyloxybutyl)- l,3-dihydro-2H-indol-2-one and l-(3-metoxyphenyl)-piperazine. M.p.: 208-211 °C.
- the title compound is prepared according to process B by applying processing method 1 starting from 3-(4-chlorobutyl)-3- ethyl-5-fluoro-l,3-dihydro-2H-indol-2-one and l-(7-chloro-2,3- dihydrobenzo[ 1 ,4]dioxin-5-yl)-piperazine.
- processing method 1 starting from 3-(4-chlorobutyl)-3- ethyl-5-fluoro-l,3-dihydro-2H-indol-2-one and l-(7-chloro-2,3- dihydrobenzo[ 1 ,4]dioxin-5-yl)-piperazine.
- the title compound is prepared according to process B by applying processing method 2 starting from 3-(4-chlorobutyl)-3- ethyl-l,3-dihydro-2H-indol-2-one and l-(5-chloro-2- metoxyphenyl)-piperazine. M.p.: 91-94 °C.
- the title compound is prepared according to process B by applying processing method 3 starting from 3-(4-chlorobutyl)-3- ethyl-5-fluoro-l,3-dihydro-2H-indol-2-one and l-(3-metoxy- phenyl)-piperazine. M.p.: 211-214 °C.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Psychiatry (AREA)
- Reproductive Health (AREA)
- Endocrinology (AREA)
- Vascular Medicine (AREA)
- Gynecology & Obstetrics (AREA)
- Hospice & Palliative Care (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Indole Compounds (AREA)
Abstract
The present invention is concerned with new indol-2-one derivatives of Formula (I), which have favourable activity profile for the prophylaxis and treatment of disorders in the central nervous or in the cardiovascular system.
Description
PIPERAZΓNE DERΓVATΓVES OF ALKYL OXMDOLES
TECHNICAL FIELD OF THE INVENTION
The invention relates to new, substituted indol-2-one derivatives and pharmaceutically acceptable acid addition salts thereof, furthermore to a process for the preparation of said compounds. The invention also encompasses pharmaceutical compositions containing said new indol-2-one derivatives and the use of said compounds for the treatment of diseases.
More particularly the present invention is concerned with new indol-2-one derivatives of the general Formula (I), R5
wherein
R1 and R2 independently represent hydrogen, halogen, alkyl or alkoxy having 1-7 carbon atom(s) or trifluoromethyl; R3 is hydrogen; - Q represents nitrogen, R4 and R5 independently represent hydrogen, halogen, trifluoromethyl, straight or branched chain alkyl or alkoxy having 1 to 7 carbon atom(s) and R6 denotes hydrogen, halogen, alkyl or alkoxy having 1 to 7 carbon atom(s), or R4 and R5 together form ethylenedioxy; or Q is a CH group and R4 and R5 together form ethylenedioxy, and R6 stands for halogen or alkoxy having 1 to 7 carbon atom(s), or Q is a CH group and R4, R5 and R6 independently represent alkyl or alkoxy having 1 to 7 carbon atom(s) or halogen; m is 1, 2, 3 or 4, and.pharmaceutically acceptable acid addition salts thereof.
TECHNICAL BACKGROUND OF THE INVENTION
U.S. patent No. 4,452,808 discloses 4-aminoalkyl indol-2-one derivatives having a selective D2 receptor activity. These compounds can be used for the treatment of hypertension. One of the compounds provided by said patent, namely 4-[2-(di-N- propylamino)ethyl]-2(3H)-indolone, is used for the clinical treatment of Parkinson disease.
European patent No. 281,309 provides indol-2-one derivatives carrying an arylpiperazinyl-alkyl substituent in position 5, which can be applied for the treatment of psychotic conditions. One of the compounds described in said patent, namely 5-[2-[4-(l,2- benzisothiazol-3-yl)-l-piperazinyl]-ethyl]-6-chloro-l,3-dihydro- 2H-indol-2-one, exerts its activity by interaction with D2, 5-HT]A and 5-HT2 receptors and is used in the clinical treatment as an antipsychotic agent.
European patent No. 376,607 discloses indol-2-one derivatives substituted in position 3 by an alkylpiperazinyl-aryl group, which exert their activity on 5-HTιA receptor and are useful for the treatment of central nervous disorders.
In the international patent application WO 98/008816 indol-2- one derivatives containing a substituted alkyl-piperazinyl, substituted alkyl-piperidinyl or alkyl-cyclohexyl group in position 3 are disclosed. These compounds possess psychotrophic activity. Said patent specification is completely silent in mentioning anything about the activity profile of the said compounds, and as a field of application only the treatment of depression and anxiety are mentioned.
The acceleration of technical-social development in the twentieth century constitutes a permanent compulsion of adaptation for humans, which, in adverse cases, may lead to the occurrence of adaptation disorders. Adaptation disorders constitute an important risk factor in the development of diseases of mental or psycho-somatic origin, such as anxiolytic syndrome, stress disorder, depression, schizophrenia, disorders of the sense organs, gastrointestinal diseases, cardiovascular diseases and disorders of the secretory organs.
For the treatment of the above clinical patterns most widespreadly pharmaceuticals exerting their activity on the benzodiazepine system (e.g. diazepam) or on central 5-HTιA receptors (e.g. buspiron, ziprasidon) have been applied. In case of psychosomatic diseases anxiolytic therapy is often complemented by the administration of pharmaceuticals possessing antihypertensive (acting on α.] or α2 receptors), or antiulcerative (Hi -receptor antagonist) activity.
Anxiolytics of benzodiazepine type are accompanied, however, by several unpleasant side-effects. They have a strong sedative activity, cause decline of the power of concentration and memory and possess muscle relaxant effect. Said side-effects influence the quality of life of the patients in an adverse manner and thus
restrict the scope of application of such pharmaceuticals.
Beside the stress occurring during adaptation to the environment another great problem of modern society is the rapid ageing of population. Owing to the results of modern medical science life expectancy has increased, and the diseases occurring due to ageing or developing in the declining years, particularly the number of mental diseases has grown in leaps and bounds. The solution of the treatment of Alzheimer's disease, vascular dementias and senile dementia has become a social problem.
As a result of the enumerated processes there is a strong need for new and efficient pharmaceuticals ensuring a more effective treatment of these diseases than those available for the time being.
SUMMARY OF THE INVENTION
The object of the present invention is to develop pharmaceutical ingredients having more favourable activity profile than those applied for the time being, which are devoid of the above- specified drawbacks and undesired side-effects and which, at the same time, can be used for the treatment and prophylaxis of disorders of the central nervous and cardiovascular system.
The invention is based on the surprising recognition that the substituted indol-2-one derivatives of the general Formula (I) - in contrast to the prior art compounds of similar structure - show a considerable binding to both 5-HT and a.\ receptors. Accordingly, it can be expected that their applicability will encompass the treatment of both central nervous and cardiovascular disorders.
DETAILED DESCRIPTION OF THE INVENTION
According to an aspect of the present invention there are provided novel 3-substituted indol-2-on derivatives of the general Formula (I), wherein
R1 and R2 independently represent hydrogen, halogen, alkyl or alkoxy having 1-7 carbon atom(s) or trifluoromethyl,
R3 is hydrogen;
Q represents nitrogen,
R4 and R5 independently represent hydrogen, halogen, trifluoromethyl, straight or branched chain alkyl or alkoxy having 1 to 7 carbon atom(s),
R6 denotes hydrogen, halogen, alkyl or alkoxy having 1 to 7 carbon atom(s), or
R4 and R5 together form ethylenedioxy; or
Q is a CH group and R4 and R5 together form ethylenedioxy, and R6 stands for halogen or alkoxy having 1 to 7 carbon atom(s), or
Q is a CH group and R4, R5 and R6 independently represent alkyl or alkoxy having 1 to 7 carbon atom(s) or halogen;
m is 1, 2, 3 or 4,
and pharmaceutically acceptable acid addition salts thereof.
The term „alkyl" used throughout this specification is intended to mean straight or branched chain saturated hydrocarbon groups having 1 to 7, preferably 1 to 4 carbon atom(s), (e.g. methyl, ethyl, 1-propyl, 2-propyl, n-butyl, isobutyl or tert. butyl group etc.)
The term „halogen" encompasses the fluorine, chlorine, bromine and iodine atoms and is preferably chlorine or bromine.
The leaving group can be an alkylsulfonyloxy or arylsulfonyloxy group, e.g. methylsulfonyloxy (mesyloxy) or p- toluenesulfonyloxy group; or a halogen atom, preferably bromine or chlorine.
The term "pharmaceutically acceptable acid addition salts" relates to non-toxic salts of the compounds of the general Formula (I) formed with pharmaceutically acceptable organic or inorganic acids. Inorganic acids suitable for salt formation are e.g. hydrogen chloride, hydrogen bromide, phosphoric, sulfuric or nitric acid. As organic acids formic, acetic, propionic, maleic, fumaric, succinic, lactic, malic, tartaric, citric, ascorbic, malonic, oxalic, mandelic, glycolic, phtalic, benzenesulfonic, p-toluene- sulfonic, naphthalic or methanesulfonic acids can be used. Furthermore, carbonates and hydrocarbonates are also considered as pharmaceutically acceptable salts.
To a preferable group of the compounds of the general Formula
(I) belong the compounds wherein Q is nitrogen;
R and R independently represent hydrogen, halogen, alkyl or alkoxy having 1 to 7 carbon atom(s) or trifluoromethyl;
R3 is hydrogen;
R4 and R5 independently represent hydrogen, halogen, trifluoromethyl or straight or branched chain alkyl or alkoxy
having 1 to 7 carbon atom(s),
R6 is hydrogen, halogen, alkyl or alkoxy having 1 to 7 carbon atom(s), or
R4 and R5 together form ethylenedioxy; m is 1, 2, 3 or 4; and pharmaceutically acceptable acid addition salts thereof.
To another preferable group of the compounds of the general formula (I) belong the compounds wherein
R1 and R2 independently represent hydrogen, halogen, alkyl or alkoxy having 1 to 7 carbon atom(s) or trifluoromethyl,
R is hydrogen;
Q is a CH group and R4 and R5 together form ethylenedioxy, R 6 denotes halogen or alkoxy having 1 to 7 carbon atom(s), or
Q is a CH group and R4, R5 and R6 independently represent halogen or alkyl or alkoxy having 1 to 7 carbon atom(s), m is 1, 2, 3 or 4; and pharmaceutically acceptable acid addition salts thereof.
Particularly preferable representatives of the compounds of general Formula (I) are the following derivatives: 3-{4-[4-(7-chloro-2,3-dihydrobenzo[l,4]dioxin-5-yl)-piperazine- 1 -yl]-butyl} -5-fluoro- 1 ,3 -dihydro-2H-indol-2-one,
3- {4-[4-(5-chloro-2-methoxyphenyl)-piperazine- 1 -yl]-butyl} - 1 ,3- dihydro-2H-indol-2-one,
5-fluoro-3- {4-[4-(3-methoxyphenyl)-piperazine-l -yl]-butyl} -1 ,3- dihydro-2H-indol-2-one, and pharmaceutically acceptable acid addition salts thereof.
According to a further aspect of the present invention there is provided a process for the preparation of the compounds of the general Formula (I) and pharmaceutically acceptable acid addition salts thereof, which comprises
a./ reacting a compound of the general Formula (II),
wherein L is hydroxy, with an arylsulfonyl chloride or a straight or branched chain alkylsulfonyl chloride having 1 to 7 carbon atom(s), preferably methylsulfonyl chloride, in the presence of an organic base, and reacting the thus- obtained compound of the general Formula (II), wherein L is aryl- or alkylsulfonyloxy, with a piperazine derivative of the general Formula (III)
in the presence of an acid binding agent, or
b./ reacting a compound of the general Formula (V), R1
• 1 9 ^ wherein R , R , R are as stated above, with a compound of the general Formula (VI), R5
wherein R4, R5, R6 is as defined above, m is 1, 2, 3 or 4, L is a leaving group, preferably chlorine or bromine, in the presence of a strong base.
The compounds of the general Formula (I), wherein R!-R6, m and Q are as stated above, can be prepared by reacting a compound of the general Formula (II), wherein R!-R3 and m are as stated above, L is a leaving group, preferably alkyl- sulfonyloxy, most preferably methylsulfonyloxy, with a compound of the general Formula (III), wherein R4-R6 and Q are as stated above, according to methods known from the literature [Houben-Weyl: Methoden der organischen Chemie, Georg Thieme Verlag, Stuttgart, 1992, 4th Edition, vol. E16d (ed.: D. Klamann); R. C. Larock: Comprehensive Organic Transformations, 2. kiadas, John Wiley & Sons, New York, 1999, 789; D. A. Walsh, Y-H. Chen, J. B. Green, J. C. Nolan, J. M. Yanni J Med. Chem. 1990, 33, 1823-1827].
During the preparation of the compounds of the general Formula (II) the formation of the substituents can be carried out in optional succession according to methods known from the literature. It is expedient to prepare the compounds of the general Formula (II) by reacting a compound of the general Formula (IV),
L-(CH2)m-L' (IV)
wherein L and n are as stated above and L' is a leaving group or a group that can be converted into a leaving group, with a compound of the general Formula (V), wherein R!-R4 are as stated above, which has been prepared according to methods known from the literature [Houben-Weyl: Methoden der organischen Chemie, Georg Thieme Verlag, Stuttgart, 1977, 4th Edition, vol. V/2b; A. R. Katritzky, Ch. W. Rees: Comprehensive Heterocyclic Chemistry, 1th Edition, Pergamon, Oxford, 1984, vol. 4. (ed.: C. W. Bird, G. W. H. Cheeseman), 98-150 and 339-366; G. M. Karp Org. Prep. Proc. Int. 1993, 25, 481-513; B. Volk, T. Mezei, Gy. Simig Synthesis 2002, 595- 597].
The compounds of the general Formula (I), wherein R'-R6 and m are as stated above, can also be prepared by reacting a compound of the general Formula (V), wherein R!-R3 are as stated above, with a compound of the general Formula (VI), wherein R4-R6, m and Q are as stated above and L is a leaving group, by methods known from the literature [R. J. Sundberg: The chemistry of indoles, Academic Press, New York, 1970, vol. VII. ; A. R. Katritzky, Ch. W. Rees: Comprehensive Heterocyclic Chemistry, 1th Edition, Pergamon, Oxford, 1984, vol. 4. (ed.: C. W. Bird, G. W. H. Cheeseman), 98-150 and 339-366; G. M. Karp Org. Prep. Proc. Int. 1993, 25, 481-513; A. S. Kende, J. C. Hodges Synth.
Commun. 1982, 12, 1-10; W. W. Wilkerson, A. A. Kergaye, S. W. Tam J. Med. Chem. 1993, 36, 2899-2907].
The compounds of the general Formula (I), wherein R'-R6, m and Q are as stated above, can also be prepared by carrying out the formation of the substituents R'-R in different succession in the last reaction step. In this case a compound of the general Formula (I) is used as starting substance wherein all substituents are as stated above except the one to be formed, which can be any one selected from R1, R2, R3, R4, R5 and R6 The introduction and conversion of the substituents are carried out according to methods known from the literature [Houben-Weyl: Methoden der organischen Chemie, Georg Thieme Verlag, Stuttgart, 1977, 4th Edition, TvVla-d; V/2b kδtet]. During the introduction of the substituents application or elimination of protecting groups may become necessary. Such methods are specified in T. W. Greene, Protective groups in organic synthesis, John Wiley & Sons, 1981.
The compounds of the general Formulae (III), (IV), (V) and (VI) are known from the literature or can be produced by analogous methods.
The compounds of the general Formula (I) can be set free from their salts or converted into pharmaceutically acceptable acid addition salts according to methods known from the literature.
According to a further aspect of the present invention there are provided pharmaceutical compositions comprising as active ingredient a compound of the general Formula (I) or a pharmaceutically acceptable acid addition salt thereof in admixture with one or more conventional carrier(s) or auxiliary agent(s).
The pharmaceutical compositions according to the present invention contain generally 0,1-95 % by weight, preferably 1-50 % by weight, particularly 5-30 % by weight of the active ingredient.
The pharmaceutical compositions of the present invention may be suitable for oral (e.g. powders, tablets, coated tablets, capsules, microcapsules, pills, solutions, suspensions or emulsions), parenteral (e.g. injection solutions for intravenous, intramuscular, subcutaneous or intraperitoneal use), rectal (e.g. suppositories) transdermal (e.g. plasters) or local (e.g. ointments or plasters) administration or for the application in form of implants. The solid, soft or liquid pharmaceutical compositions
according to the invention may be produced by methods conventionally applied in the pharmaceutical industry.
The solid pharmaceutical compositions for oral administration containing the compounds of the general Formula (I) or pharmaceutically acceptable acid addition salts thereof may comprise fillers or carriers (such as lactose, glucose, starch, calcium phosphate, micro-crystalline cellulose), binding agents (such as gelatine, sorbite, polyvinyl pyπolidone), disintegrants (such as croscarmelose, Na-carboxymethyl cellulose, crospovidone), tabletting auxiliary agents (such as magnesium stearate, talc, polyethylene glycol, silicic acid, silicon dioxide) and surface-active agents (e.g. sodium lauryl sulfate).
The liquid compositions suitable for oral administration can be solutions, suspensions or emulsions. Such compositions may contain suspending agents (e.g. gelatine, carboxymethyl cellulose), emulsifiers (e.g. sorbitane monooleate, solvents (e.g. water, oils, glycerol, propylene glycol, ethanol), buffering agents (e.g. acetate, phosphate, citrate buffers) and preservatives (e.g. methyl-4-hydroxyb enzoate) .
Liquid pharmaceutical compositions suitable for parenteral administration are generally sterile isotonic solutions optionally
containing, in addition to the solvent, buffering agents and preservatives.
Soft pharmaceutical compositions containing as active ingredient a compound of the general Formula (I) or a pharmaceutically acceptable acid addition salt thereof, such as suppositories, contain the active ingredient evenly dispersed in the basic material of the suppository (e.g. in polyethylene glycol or cocoa butter).
According to a further aspect of the present invention there is provided the use of 3-substituted indol-2-one derivatives of the general Formula (I) or a pharmaceutically acceptable acid addition salt thereof for the preparation of pharmaceutical compositions suitable for the treatment or prophylaxis of central nervous disorders or psychosomatic diseases, particularly generalized anxiety disorders, panic disease, compulsive disorder, social phobia, agoraphobia, phobias in connection with specific situations, post-traumatic stress disorders, post-traumatic memory disturbances, cognitive disorders, sexual dysfunction of central nervous system origin, depression, schizophrenia; gastrointestinal diseases and cardiovascular diseases.
The pharmaceutical compositions according to the present invention can be prepared by known methods of the pharmaceutical industry. The active ingredient is admixed with pharmaceutically acceptable solid or liquid carriers and/or auxiliary agents and the mixture is brought to galenic form. The carriers and auxiliary agents together with the methods which can be used in the pharmaceutical industry are disclosed in the literature (Remington's Pharmaceutical Sciences, Edition 18, Mack Publishing Co., Easton, USA, 1990).
The pharmaceutical compositions according to the present invention contain generally a dosage unit. The daily dosage for human adults can be generally 0,1-1000 mg/kg body weight of a compound of the general Formula (I) or a pharmaceutically acceptable acid addition salts thereof. Said daily dose can be administered in one or more portion(s). The actual daily dose depends on several factors and is determined by the physician.
According to a further aspect of the present invention there is provided the use of the compounds of the general Formula (I) or pharmaceutically acceptable acid addition salts thereof for the treatment or prophylaxis of disorders of the central nervous system and psychosomatic disorders including anxiety syndrome, particularly generalized anxiety disorders, panic disease,
compulsive disorder, social phobia, agoraphobia, phobias in connection with specific situations, stress disorders, post- traumatic stress disorders, post-traumatic memory disturbances, cognitive disorders, sexual dysfunction of central nervous system origin, depression, schizophrenia, neurodegeneration followed by mental decline, Alzheimer's disease, stroke, dementias, furthermore gastrointestinal diseases and cardiovascular diseases, particularly hypertension.
The invention is based on the surprising recognition that the 3- alkyl-indol-2-one derivatives of the general Formula (I) - in contrast to the prior art compounds of similar structure - show a considerable binding to both 5-HT7, and ci] receptors.
For the determination of 5-HT receptor affinity human cloned receptors were used. The receptor affinities were determined from isolated frontal cortex preparation of male Wistar rats weighing 120-200 g. The protein contents of membrane preparations were determined by the method of Lowry (1951).
In the course of 5-HT7 and αi receptor binding studies the ligands were 3H-lizergic acid diethylamide (LSD) (1.0 nM) and 3H- prazosine (0.3 nM). Clozapine (25 μM) and prazosine (1 μM) were used for the measurement of non-specific bindings. The αi
receptor binding studies were carried out according to the methods of Reader, and Greengrass (Reader, T.A., Briere, R., Grondin, L.: J. Neural Transm. 68, p. 79 (1987); Greengrass, P., Brenner, R.: Eur. J. Pharmacol. 55, p. 323 (1979) ).
IC50 is the concentration where the difference between the whole binding and non-specific binding is 50%. The compounds with an IC50 value smaller than 100 nmol were considered effective in this test. The results of the experiments are presented in Tables 2 and 3.
Table 1 5-HT7 receptor binding
Table 2 αi receptor binding
As it can be seen from the data shown in Tables 1 and 2, the compounds according to the invention considerably bind to the 5-HT7 and αi receptors.
On the basis of the above experiments it can be established that the compounds according to the invention possess a valuable therapeutic profile rendering them suitable for the treatment or prophylaxis of mental and cardiovascular diseases, especially those specified above.
Further details of the present invention are provided in the following examples without limiting the scope of protection to said examples.
Preparation of mesyl esters (process „A")
The appropriate 3-(4-hydroxybutyl)-oxindoles are prepared according to a method known from the literature [B. Volk, T. Mezei, Gy. Simig Synthesis 2002, 595; B. Volk, Gy. Simig Eur. J. Org. Chem. 2003, 18, 3991-3996].
55 mmoles of 3-(4-hydroxybutyl)-oxindole are dissolved in 150 ml of THF, 15.2 ml (110 mmoles) of triethyl amine are added to it, and the solution is cooled in an acetone-dry ice bath to -78 °C. While stirring at the same temperature 8.5 ml (110 mmoles) of mesyl chloride are added dropwise to it and the solution is allowed to warm to room temperature. It is stirred at room temperature for 1 hour, the triethyl amine hydrochloride is filtered off, the filtrate is evaporated, the residue is taken up in ethyl acetate and extracted several times with 10 % by volume hydrogen chloride solution until the pH of the aqueous phase has become acidic. The organic phase is dried over sodium sulfate, evaporated, the residual oil is crystallized by rubbing it with diisopropyl ether, stiπed in 100 ml of diisopropyl ether, filtered, washed with hexane and dried. The product is purified by
recrystallization from the solvent indicated after the melting point of the given substance.
Example 1 3 -(4-Mesyloxybutyl)- 1 ,3 -dihydro-2H-indol-2-one
The title compound is prepared according to process A starting from 3-(4-hydroxybutyl)-l ,3-dihydro-2H-indol-2-one. M.p.: 84-85 °C (heptane-ethyl acetate).
IR (KBr): 3180, 1705 (C=O) cm-'.
1H-NMR (CDC13, TMS, 400 MHz): 9.33 (IH, s), 7.22 (IH, d, J
= 7.1 Hz), 7.21 (IH, t, J = 7.0 Hz), 7.03 (IH, t, J = 7.5 Hz), 6.93
(IH, d, J = 7.6 Hz), 4.19 (2H, t, J = 6.5 Hz), 3.49 (IH, t, J = 6.0
Hz), 2.97 (3H, s), 2.05-1.98 (2H, m), 1.82-1.72 (2H, m) 1.58-
1.40 (2H, m) ppm.
13C-NMR (CDC13, TMS, 101 MHz): 180.5, 141.6, 129.1, 127.9, 123.9, 122.3, 109.9, 69.5, 45.7, 37.2, 29.6, 28.9, 21.6 ppm.
Example 2 5-Fluoro-3-(4-mesyloxybutyl)-l,3-dihydro-2H-indol-2-one
The title compound is prepared according to process A starting from 5-fluoro-3-(4-hydroxybutyl)-l ,3-dihydro-2H-indol-2-one. M.p.: 106-108 °C (hexane-ethyl acetate).
IR (KBr): 3169, 1702 (C=O), 1356, 1175 (SO2) cm"1.
Η-NMR (CDC13, TMS, 500 MHz): 1.43-1.55 (2H, m), 1.73- 1.83 (2H, m), 1.97-2.05 (2H, m), 2.99 (3H, s), 3.50 (IH, t, J = 5.9 Hz), 4.21 (2H, dq, J = 1.4, 6.3 Hz), 6.86 (IH, dd, J = 4.3, 8.4 Hz), 6.93 (IH, dt, J = 2.3, 9.0 Hz), 6.97 (IH, dd, J = 2.0, 7.3 Hz), 9.22 (IH, s) ppm.
13C-NMR (CDC13, TMS, 125.6 MHz): 180.2, 158.9 (d, J - 240.6 Hz), 137.5 (d, J = 1.7 Hz), 130.8 (d, J = 8.5 Hz), 114.3 (d, J = 27.5 Hz), 111.9 (d, J = 24.8 Hz), 110.4 (d, J = 8.1 Hz), 69.4, 46.2, 37.3, 29.5, 28.9, 21.5 ppm.
Example 3 6-Fluoro-3-(4-mesyloxybutyl)- 1 ,3-dihydro-2H-indol-2-one
The title compound is prepared according to process A starting from 6-fluoro-3-(4-hydroxybutyl)- 1 ,3-dihydro-2H-indol-2-one. M.p.: 106-108 °C (hexane-ethyl acetate).
IR (KBr): 3161, 1705 (CO), 1335, 1313, 1167 (SO2) cm"1.
1H-NMR (CDC13, TMS, 500 MHz): 1.46-1.51 (2H, m), 1.78 (2H, kv, J - 6.7 Hz), 2.00 (2H, q, J = 8.1 Hz), 2.99 (3H, s), 3.46 (IH, t, J = 5.9 Hz), 4.21 (2H, dt, J = 1.5, 6.5 Hz), 6.68 (IH, dd, J = 2.3, 8.8 Hz), 6.72 (IH, dt, J = 2.3, 8.9 Hz), 7.15 (IH, dd, J = 5.4, 8.1 Hz), 9.15 (lH, br s) ppm.
13C-NMR (CDC13, TMS, 125.6 MHz): 21.6, 28.9, 29.7, 37.3, 45.3, 69.5, 98.6 (d, J = 27.4 Hz), 108.7 (d, J = 22.5 Hz), 124.5 (d, J = 3.0 Hz), 124.9 (d, J = 9.5 Hz), 142.8 (d, J - 11.8 Hz), 162.6 (d, J = 244.6 Hz), 180.7 ppm.
Example 4 5-Methyl-3 -(4-mesyloxybutyl)- 1 ,3 -dihydro-2H-indol-2-one
The title compound is prepared according to process A starting from 3-(4-hydroxybutyl)-5-methyl- 1 ,3-dihydro-2H-indol-2-one. M.p.: 89-90 °C (hexane-ethyl acetate).
IR (KBr): 3175, 1710 (C=O), 1351, 1176 (SO2) cm"1.
Η-NMR (CDC13, TMS, 400 MHz): 9.13 (IH, s), 7.03 (IH, s), 7.01 (IH, dd, J = 7.9, 0.8 Hz), 6.81 (IH, d, J = 7.9 Hz), 4.20
(2H, t, J = 6.5 Hz), 3.45 (IH, t, J - 5.9 Hz), 2.98 (3H, s), 2.33 (3H, s), 1.99 (2H, q, J = 7.4 Hz), 1.79-1.75 (2H, m), 1.51-1.42 (2H, m) ppm.
13C-NMR (CDC13, TMS, 101 MHz): 180.4, 139.1, 131.7, 129.2, 128.2, 124.7, 109.5, 69.6, 45.8, 37.2, 29.6, 28.9, 21.5, 21.0 ppm.
Coupling reaction of mesyl esters with bases (process „B")
The melt of the secondary amine (12 mmoles) is warmed to 120 °C under slow stirring, and the mesyl compound (12 mmoles) and sodium carbonate (1.36 g; 12 mmoles) are added to it at the same temperature. The mixture is allowed to react for 1 hour, the melt is allowed to cool, ethyl acetate and water are added to it and the phases are separated. The organic phase is evaporated, the residual oil is subjected to chromatography on a short column using ethyl acetate as eluent. As main products the desired compounds are obtained.
Processing method 1 : If the product purified by column chromatography gets crystalline upon rubbing with diethyl ether, it is filtered off and recrystallized from a mixture of hexane and ethyl acetate. The desired compounds are obtained in form of white crystals.
Processing method 2: If the basic product does not get crystalline upon the addition of diethyl ether, it is dissolved in 200 ml of ether, the slight amount of floating precipitate is filtered off and to the pure solution the calculated amount (1 molar equivalent) of hydrogen chloride dissolved in ether diluted with 50 ml of diethyl ether is dropped under vigorous stirring. The separated white salt is filtered off, washed with ether and hexane and dried in a vacuum pistol at room temperature for 3 hours. Processing method 3: If the basic product does not get crystalline upon the addition of diethyl ether and does not provide a well- filterable salt with hydrogen chloride, it is dissolved in 100 ml of hot ethyl acetate, and a solution of 1 molar equivalent of oxalic acid dihydrate in 30 ml of hot ethyl acetate is dropped to it within 10 minutes, under stirring. The white oxalate salt gets separated upon cooling. It is filtered off at room temperature, washed with ethyl acetate and hexane and dried.
Example 5 3-[4-(4-Pyridin-2-yl-piperazine- 1 -yl)-butyl]- 1 ,3-dihydro-2H- indol-2-one
The title compound is prepared according to process B by applying processing method 1 starting from 3-(4-mesyloxybutyl)-
l,3-dihydro-2H-indol-2-one and l-(pyridin-2-yl)-piperazine. M.p.: 131-132 °C (hexane-ethyl acetate).
IR (KBr): 3189, 1706 (C=O), 1665 cm"
1H-NMR (CDC13, TMS, 400 MHz): 1.59-1.38 (4H, m), 2.05- 1.95 (2H, m), 2.35 (2H, t, J = 7.5 Hz), 2.51 (4H, t, J = 5.1 Hz), 3.47 (IH, t, J = 5.9 Hz), 3.52 (4H, t, J = 5.1 Hz), 6.61 (IH, t, J = 6.1 Hz), 6.62 (IH, d, J = 8.7 Hz), 6.89 (IH, d, J = 7.7 Hz), 7.01 (IH, dt, J = 1.0, 7.5 Hz), 7.20 (IH, t, J = 7.8 Hz), 7.22 (IH, d, J - 7.0 Hz), 7.45 (IH, dt, J = 2.0, 7.9 Hz), 8.18 (IH, ddd, J = 0.8, 2.0, 4.9 Hz) ppm.
,3C-NMR (CDCI3, TMS, 101 MHz): 180.6, 159.5, 147.8, 141.7, 137.3, 129.7, 127.8 ,124.0, 122.1, 113.2, 109.7, 107.0, 58.3, 52.9, 46.0, 45.1, 30.2, 26.7, 23.7 ppm.
Analysis for the formula C2]H26N4O (350.47): Calculated: C 71.97, H 7.48, N 15.99 %. Found: C 70.86, H 7.48, N 15.76 %.
Example 6
3-{4-[4-(7-Chloro-2,3-dihydrobenzo[l,4]dioxin-5-yl)-piperazine- 1 -yl]-butyl} - 1 ,3-dihydro-2H-indol-2-one monooxalate
The title compound is prepared according to process B by applying processing method 3 starting from 3-(4-mesyloxybutyl)- l,3-dihydro-2H-indol-2-one and l-(7-chloro-2,3-dihydrobenzo- [l,4]dioxin-5-yl)-piperazine. M.p.: 236-238 °C.
IR (KBr): 3273, 3013, 1710 (CO) cm"1.
Η-NMR DMSO-d6, TMS, 400 MHz): 1.38-1.22 (2H, m), 1.70- 1.60 (2H, m), 1.95-1.75 (2H, m), 2.95 (2H, t, J - 7.5 Hz), 3.18 (8H, br s), 3.44 (IH, t, J = 6.1 Hz), 4.25 (4H, s), 6.64 (IH, d, J = 2.4 Hz), 6.50 (IH, d, J = 2.4 Hz), 6.84 (IH, d, J = 7.7 Hz), 6.95 (IH, t, J = 7.5 Hz), 7.17 (IH, t, J = 7.6 Hz), 7.26 (IH, d, J = 7.3 Hz), 8.7 =2H, br s), 10.4 (IH, s) ppm.
13C-NMR (DMSO- 6, TMS, 101 MHz): 179.0, 164.7, 144.6, 142.9, 141.2, 135.1, 129.7, 127.8, 124.4, 124.2, 121.4, 111.4, 110.7, 109.4, 64.2, 64.1, 55.7, 51.2, 47.3, 45.1, 29.6, 23.7, 22.8 ppm.
Analysis for the formula C26H30C1N3O7 (532.00): Calculated: C 58.70 H 5.68 CI 6.66 N 7.90 %.
Found: C 58.67 H 5.77 CI 6.67 N 7.85 %.
Example 7 5-Fluoro-3-[4-(4-pyridin-2-yl-piperazine-l-yl)-butyl]-l,3- dihydro-2H-indol-2-one
The title compound is prepared according to process B/1 starting from 5-fluoro-3-(4-mesyl-oxybutyl)-l ,3-dihydro-2H-indol-2-one and l-(pyridin-2-yl)-piperazine. M.p.: 132-134 °C (hexane-ethyl acetate).
IR (KBr): 3180, 1705 (CO) cm"1.
1H-NMR (CDC13, TMS, 400 MHz): 1.47-1.35 (2H, m), 1.59- 1.52 (2H, m), 2.03-1.95 (2H, m), 2.36 (2H, t, J = 7.6 Hz), 2.52 (4H, t, J = 5.1 Hz), 3.48 (IH, t, J = 5.9 Hz), 3.53 (4H, t, J = 5.0 Hz), 6.64-6.59 (2H, m), 6.81 (IH, dd, J = 4.3, 8.5 Hz), 6.91 (IH, dt, J = 2.6, 9.2 Hz), 6.97 (IH, dd, J = 2.0, 7.9 Hz), 7.47 (IH, dt, J = 2.0, 7.1 Hz), 8.18 (IH, ddd, J = 0.9, 2.0 Hz), 9.00 (IH, s) ppm.
13C-NMR (CDCI3, TMS, 101 MHz): 23.6, 26.7, 30.2, 45.1, 46.4, 53.0, 58.3, 107.0, 110.1 (d, J = 8.0 Hz), 112.1 (d, J - 24.4 Hz), 113.2, 114.1 (d, J = 23.3 Hz), 131.3 (d, J = 7.6 Hz), 137.4, 137.5, 147.9, 159.0 (d, J = 239.9 Hz), 159.5, 180.2 ppm.
Analysis for the formula C2jH25FN4O (368.46): Calculated: C 68.46 H 6.84 N 15.21 %.
Found: C 68.34 H 7.04 N 14.86 %.
Example 8 6-Fluoro-3 -[4-(4-pyridin-2-yl-piperazine- 1 -yl)-butyl] -1,3- dihydro-2H-indol-2-one
The title compound is prepared according to process B by applying processing method 1 starting from 6-fluoro-3-(4- mesyloxybutyl)-l,3-dihydro-2H-indol-2-one and l-(pyridin-2- yl)-piperazine.
M.p.: 136-137 °C (hexane-ethyl acetate).
DR. (KBr): 3294, 1726 (CO), 1689 cm"1.
Η-NMR (CDCI3, TMS, 400 MHz): 1.43-1.38 (2H, m), 1.67 (2H, br s), 1.97 (2H, q, J = 7.4 Hz), 2.55 (2H, br s), 2.74 (4H, br s), 3.42 (IH, t, J = 5.9 Hz), 3.68 (4H, br s), 6.73-6.63 (4H, m), 7.13
(IH, dd, J = 5.3, 8.2 Hz), 7.48 (IH, dt, J = 2.0, 7.8 Hz), 8.20- 8.17 (lH, m), 8.97 (lH, s) ppm.
13C-NMR (CDC13, TMS, 101 MHz): 23.3, 25.6, 30.1, 44.3, 45.3, 52.5, 57.9, 98.4 (d, J = 27.1 Hz), 107.2, 108.5 (d, J = 22.1 Hz), 113.8, 124.7 (d, J = 3.1 Hz), 124.9 (d, J = 9.9 Hz), 137.6, 142.9 (d, J = 12.2 Hz),147.9, 159.0, 162.6 (d, J = 244.5 Hz), 180.4 ppm.
Analysis for the formula C2ιH25FN4O (368.46): Calculated: C 68.46 H 6.84 N 15.21 %.
Found: C 68.14 H 6.83 N 15.03 %.
Example 9
3- {4-[4-(3-Methoxyphenyl)-piperazine- 1 -yl]-butyl} - 1 ,3-dihydro- 2H-indol-2-one monooxalate
The title compound is prepared according to process B by applying processing method 3 starting from 3-(4-mesyloxybutyl)- l,3-dihydro-2H-indol-2-one and l-(3-metoxyphenyl)-piperazine. M.p.: 208-211 °C.
IR (KBr): 3160, 2579, 2456, 1707 (CO) cm"1.
Η-NMR (DMSO-d6, TMS, 400 MHz): 1.36-1.24 (2H, m), 1.95- 1.72 (4H, m), 3.09-3.00 (2H, m), 3.16 (2H, t, J = 11.9 Hz), 3.46 (IH, t, J= 6.1 Hz), 3.47 (2H, t, J= 10.4 Hz), 3.73 (3H, s), 3.78 (2H, d, J= 13.0 Hz), 10.4 (IH, s), 11.1 (IH, br s) ppm.
13C-NMR DMSO-d6, TMS, 101 MHz): 22.7, 23.1, 29.6, 45.0, 45.4, 50.5, 50.6, 55.1, 55.2, 102.1, 105.2, 108.3, 109.2, 121.2, 124.0, 127.6, 129.5, 129.8, 142.7, 150.9, 160.2, 178.7 ppm.
Analysis for the formula C25H3jN3O6 (469.54): Calculated: C 63.95 H 6.65 N 8.95 %.
Found: C 63.80 H 6.81 N 8.81 %.
Example 10
3- {4-[4-(7-Chloro-2,3-dihydrobenzo[l ,4]dioxin-5-yl)-piperazine- 1 -yl]-butyl} -5-fluoro- 1 ,3-dihydro-2H-indol-2-one
The title compound is prepared according to process B by applying processing method 1 starting from 3-(4-chlorobutyl)-3- ethyl-5-fluoro-l,3-dihydro-2H-indol-2-one and l-(7-chloro-2,3- dihydrobenzo[ 1 ,4]dioxin-5-yl)-piperazine. M.p.: 146-148 °C (hexane-ethyl acetate).
IR (KBr): 2946, 1720 (CO), 752 cm"
1H-NMR (DMSO- , TMS, 400 MHz): 1.34-1.17 (2H, m), 1.43- 1.34 (2H, m), 1.99-1.78 (2H, m), 2.42 (4H, br s), 2.93 (4H, br s), 3.48 (IH, t, J= 5.6 Hz), 4.23 (4H, s), 6.42 (IH, d, J = 2.5 Hz), 6.56 (IH, d, J= 2.4 Hz), 6.79 (IH, dd, J- 4.5, 8.5 Hz), 6.99 (IH, dt, J= 2.7, 9.1 Hz), 7.16 (IH, dd, J= 1.8, 8.2 Hz), 10.34 (IH, s) ppm.
13C-NMR (DMSO-< , TMS, 101 MHz): 23.1, 26.3, 29.5, 45.8 (d, J = 1.9 Hz), 49.9, 52.8, 52.9, 57.7, 63.9, 64.1, 109.8 (d, J = 8.0 Hz), 110.54, 110.6, 112.0 (d, J = 24.4 Hz), 113.8 (d, J = 22.9 Hz), 124.3, 131.8 (d, J - 8.4 Hz), 135.1, 139.1 (d, J = 1.9 Hz), 142.7, 144.4, 158.0 (d, J= 235.7 Hz), 178.9 ppm.
Analysis for the formula C24H27ClFN3O3 (459.95): Calculated: C 62.67 H 5.92 CI 7.71 N 9.14 %.
Found: C 62.26 H 5.88 CI 7.53 N 8.93 %.
Example 11 3- {4-[4-(5-Chloro-2-methoxyphenyl)-piperazine- 1 -yl]-butyl} - 1 ,3-dihydro-2H-indol-2-one monohydrochloride
The title compound is prepared according to process B by applying processing method 2 starting from 3-(4-chlorobutyl)-3- ethyl-l,3-dihydro-2H-indol-2-one and l-(5-chloro-2-
metoxyphenyl)-piperazine. M.p.: 91-94 °C.
IR (KBr): 2583, 1708 (CO) cm"
1H-NMR (OMSO-d6, TMS, 400 MHz): 1.34-1.23 (2H, m), 1.92- 1.70 (4H, m), 3.15-3.00 (6H, m), 3.59-3.40 (5H, m), 3.78 (3H, s), 6.84 (IH, d, J= 7.7 Hz), 6.90 (IH, d, J= 2.5 Hz), 6.95 (IH, dt, J = 1.0, 7.4 Hz), 6.98 (IH, d, J= 8.7 Hz), 7.04 (IH, dd, J= 2.5, 8.7 Hz), 7.17 (IH, t, J= 1.1 Hz), 7.27 (IH, d, J= 7.2 Hz), 10.4 (IH, s), 11.06 (lH, br s) ppm.
13C-NMR (DMSO-</6, TMS,101 MHz): 22.7, 23.1, 29.6, 45.0, 46.6, 50.9, 55.2, 55.9, 109.4, 113.4, 118.3, 121.4, 122.7, 124.2, 124.7, 127.8, 129.7, 140.8, 142.9, 150.8, 178.9 ppm.
Analysis for the formula C23H29Cl2N3O2 (450.41): Calculated: C 61.33 H 6.49 CI 15.74 N 9.33 %.
Found: C 59.48 H 6.71 CI 15.47 N 8.96 %.
Example 12 5-Fluoro-3- {4-[4-(3-methoxyphenyl)-piperazine- 1 -yl]-butyl} - 1 ,3-dihydro-2H-indol-2-one monooxalate
The title compound is prepared according to process B by applying processing method 3 starting from 3-(4-chlorobutyl)-3- ethyl-5-fluoro-l,3-dihydro-2H-indol-2-one and l-(3-metoxy- phenyl)-piperazine. M.p.: 211-214 °C.
IR (KBr): 3226, 1708 (CO) cm"1.
Η-NMR (DMSO- e, TMS, 400 MHz): 1.28-1.15 (2H, m), 1.68- 1.64 (2H, m), 1.94-1.76 (2H, m), 2.9 (2H, t, J = 7.8 Hz), 3.18 (4H, s), 3.37 (4H, s), 3.49 (IH, t, J= 5.6 Hz), 3.72 (3H, s), 6.43 (IH, d, J = 8.0 Hz), 6.56 (IH, d, J = 8.1 Hz), 6.51 (IH, s), 6.82 (IH, dd, J = 4.4, 8.3 Hz), 7.20-7.12 (2H, m), 9.2-7.6 (2H, br s), 10.43 (lH, s) ppm.
13C-NMR (DMSO-d6, TMS, 101 MHz): 22.6, 23.6, 29.3, 45.6, 45.9, 50.9, 55.1, 55.5, 59.9, 102.2, 105.3, 108.5, 109.9 (d, J= 8.0 Hz), 112.1 (d, J= 24.4 Hz), 114.0 (d, J= 23.3 Hz), 130.0, 131.6 (d, J= 8.4 Hz), 139.2 (d, J= 1.5 Hz), 151.3, 158.1 (d, J= 235.7 Hz), 160.5, 164.5, 178.8 ppm.
Analysis for the formula C25H30FN3O6 (487.53): Calculated: C 61.59 H 6.20 N 8.62 %.
Found: C 59.70 H 6.33 N 8.35 %.
Claims
1. 3-alkyl indol-2-one derivatives of the general Formula (I), R5
wherein
1
R and R independently represent hydrogen, halogen, alkyl or alkoxy having 1-7 carbon atom(s) or trifluoromethyl;
R3 is hydrogen;
Q represents nitrogen, R4 and R5 independently represent hydrogen, halogen, trifluoromethyl, straight or branched chain alkyl or alkoxy having 1 to 7 carbon atom(s), and R6 denotes hydrogen, halogen, alkyl or alkoxy having 1 to 7 carbon atom(s), or R4 and R5 together form ethylene-dioxy; or Q is a CH group and R4 and R5 together form ethylenedioxy, and R6 stands for halogen or alkoxy having 1 to 7 carbon atom(s), or
Q is a CH group and R4, R5 and R6 independently represent alkyl or alkoxy having 1 to 7 carbon atom(s) or halogen;
m is 1, 2, 3 or 4,
and pharmaceutically acceptable acid addition salts thereof.
2. 3 -alkyl indol-2-one derivatives, wherein
Q is nitrogen;
R1 and R2 independently represent hydrogen, halogen, alkyl or alkoxy having 1-7 carbon atom(s) or trifluoromethyl;
R3 represents hydrogen;
R and R independently represent hydrogen, halogen, trifluoromethyl, straight or branched chain alkyl or alkoxy having 1 to 7 carbon atom(s), and R6 denotes hydrogen, halogen, alkyl or alkoxy having 1 to 7 carbon atom(s), or R4 and R5 together form ethylenedioxy;
m is 1, 2, 3 or 4;
and pharmaceutically acceptable acid addition salts thereof.
3. 3 -alkyl indol-2-one derivatives, wherein
R1 and R2 independently represent hydrogen, halogen, alkyl or alkoxy having 1-7 carbon atom(s) or trifluoromethyl;
R is hydrogen;
Q represents a CH group and R and R together form ethylenedioxy, R6 stands for halogen or alkoxy having 1 to 7 carbon atom(s), or
Q is a CH group and R4, R5 and R6 independently represent alkyl having 1-7 carbon atom(s), alkoxy having 1-7 carbon atom(s) or halogen;
m is 1, 2, 3 or 4; and pharmaceutically acceptable acid addition salts thereof.
4. 3-[4-(4-Pyridine-2-yl-piperazine- 1 -yl)-butyl]-l ,3-dihydro-2H- indol-2-one, and pharmaceutically acceptable acid addition salts thereof.
5. 3-{4-[4-(7-Chloro-2,3-dihydrobenzo[l,4]-dioxin-5-yl)- piperazine- 1 -yl]-butyl} - 1 ,3-dihydro-2H-indol-2-one, and pharmaceutically acceptable acid addition salts thereof.
6. 5-Fluoro-3-[4-(4-pyridin-2-yl-piperazine-l-yl)-butyl]-l,3- dihydro-2H-indol-2-one, and pharma-ceutically acceptable acid addition salts thereof.
7. 6-Fluoro-3-[4-(4-pyridin-2-yl-piperazine-l-yl)-butyl]-l,3- dihydro-2H-indol-2-one, and pharma-ceutically acceptable acid addition salts thereof.
8. 3-{4-[4-(3-Methoxyphenyl)-piperazine-l-yl]-butyl}-l,3- dihydro-2H-indol-2-one, and pharma-ceutically acceptable acid addition salts thereof.
9. 3-{4-[4-(7-Chloro-2,3-dihydrobenzo[l,4]-dioxin-5-yl)- piperazine- 1 -yl]-butyl} -5-fluoro- 1 ,3-dihydro-2H-indol-2-one, and pharmaceutically acceptable acid addition salts thereof.
10. 3-{4-[4-(5-Chloro-2-methoxyphenyl)-piperazine-l-yl]- butyl}-l,3-dihydro-2H-indol-2-one, and pharmaceutically acceptable acid addition salts thereof.
11. 5-Fluoro-3-{4-[4-(3-methoxyphenyl)-piperazine-l-yl]-butyl}- l,3-dihydro-2H-indol-2-one, and pharmaceutically acceptable acid addition salts thereof.
12. Pharmaceutical compositions comprising as active ingredient at least one of the compounds of the general Formula (I) according to any of claims 1 to 11 or a pharmaceutically acceptable acid addition salt thereof in admixture with one or more conventional carrier(s) or auxiliary agent(s).
13. A pharmaceutical composition according to claim 12 suitable for the treatment or prophylaxis of disorders of the central nervous system and psychosomatic disorders including anxiety syndrome, particularly generalized anxiety disorders, panic disease, compulsive disease, social phobia, agoraphobia, phobias connected to specific situations, stress disorders, post-traumatic stress disorders, post-traumatic memory disorder, cognitive disorder, sexual dysfunction of central nervous system origin, depression, schizophrenia, neuro-degeneration followed by mental decline, Alzheimer's disease, stroke, dementias, furthermore gastrointestinal diseases and cardiovascular diseases, particularly hypertension.
14. A process for the preparation of the compounds of the general Formula (I), wherein R1 - R6, Q and m are as stated above, which comprises
a./ reacting a compound of the general Formula (II),
wherein L is hydroxy, with an arylsulfonyl chloride or a straight or branched chain alkylsulfonyl chloride having 1 to 7 carbon atom(s), preferably methylsulfonyl chloride, in the presence of an organic base, and reacting the thus- obtained compound of the general Formula (II), wherein L is aryl or alkylsulfonyloxy, with a pyridine derivative of the general Formula (III) R5
in the presence of an acid binding agent, or
b./ reacting a compound of the general Formula (V), R1
wherein R1, R2, R3 are as stated above, with a compound of the general Formula (VI), R5
wherein R4, R5, R6 is as defined above, m is 1 , 2, 3 or 4, L is a leaving group, preferably chlorine or bromine, in the presence of a strong base.
15. Use of a 3-alkyl-indol-2-one derivative of the general Formula (I) according to any of claims 1 to 11 as a medicament.
16. A process for the manufacture of a pharmaceutical composition suitable for the treatment or prophylaxis of central nervous system and psychosomatic disorders including anxiety syndrome, particularly generalized anxiety disorders, panic disease, compulsive disorder, social phobia, agoraphobia, phobias connected to specific situations, stress dis-order, post- traumatic stress disorder, post-traumatic memory disorder, cognitive disorders, sexual dysfunction of central nervous system origin, depression, schizophrenia, mental decline caused by cerebral cytolysis, Alzheimer's disease, stroke, dementias, furthermore gastro-intestinal diseases and cardiovascular diseases, particularly hypertension, which comprises admixing at least one compound of the general Formula (I) according to any of claims 1 to 11 or a pharmaceutically acceptable acid addition salt thereof with a pharmaceutical carrier and optionally other auxiliary agent and bringing the mixture to galenic form.
17. A method for the treatment or prophylaxis of diseases of the central nervous system and psychosomatic disorders including anxiety syndrome, particularly generalized anxiety dis-order, panic disease, compulsive disease, social phobia, agoraphobia, phobias in connection with specific situations, stress disorder, post-traumatic stress disorder, post-traumatic memory disorder, cognitive disorder, sexual dysfunction of central nervous system origin, depression, schizophrenia, neurodegeneration followed by mental decline, Alzheimer's disease, stroke, dementias, furthermore gastrointestinal diseases and cardiovascular diseases, particularly hyper-tension, which comprises administering to a patient in need of such treatment an efficient amount of a pharmaceutical composition containing at least one compound of the general Formula (I) or a pharmaceutically acceptable, organic or inorganic acid addition salt thereof.
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SI200530564T SI1751105T1 (en) | 2004-05-11 | 2005-05-11 | Piperazine derivatives of alkyl oxindoles |
| PL05745440T PL1751105T3 (en) | 2004-05-11 | 2005-05-11 | Piperazine derivatives of alkyl oxindoles |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| HU0400953A HUP0400953A3 (en) | 2004-05-11 | 2004-05-11 | Piperazine derivatives of alkyl-oxindoles, pharmaceutical compositions containing them, process for producing them and their use |
| PCT/HU2005/000050 WO2005108364A1 (en) | 2004-05-11 | 2005-05-11 | Piperazine derivatives of alkyl oxindoles |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| EP1751105A1 true EP1751105A1 (en) | 2007-02-14 |
| EP1751105B1 EP1751105B1 (en) | 2008-10-29 |
Family
ID=89982207
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EP05745440A Active EP1751105B1 (en) | 2004-05-11 | 2005-05-11 | Piperazine derivatives of alkyl oxindoles |
Country Status (27)
| Country | Link |
|---|---|
| US (1) | US7910591B2 (en) |
| EP (1) | EP1751105B1 (en) |
| JP (1) | JP2007537227A (en) |
| CN (1) | CN101010296B (en) |
| AT (1) | ATE412633T1 (en) |
| AU (1) | AU2005240843B2 (en) |
| BG (1) | BG109769A (en) |
| CA (1) | CA2566096A1 (en) |
| CZ (1) | CZ2006779A3 (en) |
| DE (1) | DE602005010693D1 (en) |
| DK (1) | DK1751105T3 (en) |
| EA (1) | EA010789B1 (en) |
| ES (1) | ES2319795T3 (en) |
| HR (1) | HRP20060420A2 (en) |
| HU (1) | HUP0400953A3 (en) |
| IL (1) | IL179028A (en) |
| MX (1) | MXPA06013068A (en) |
| NO (1) | NO20065609L (en) |
| NZ (1) | NZ551545A (en) |
| PL (2) | PL381615A1 (en) |
| PT (1) | PT1751105E (en) |
| RS (1) | RS20060621A (en) |
| SI (1) | SI1751105T1 (en) |
| SK (1) | SK51102006A3 (en) |
| UA (1) | UA84927C2 (en) |
| WO (1) | WO2005108364A1 (en) |
| ZA (1) | ZA200610345B (en) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUP0400953A3 (en) * | 2004-05-11 | 2008-02-28 | Egis Gyogyszergyar Nyilvanosan | Piperazine derivatives of alkyl-oxindoles, pharmaceutical compositions containing them, process for producing them and their use |
| CN104163813B (en) * | 2013-05-16 | 2017-02-01 | 广东东阳光药业有限公司 | Substituted indole compound, and preparation method and use thereof |
| CN106243088B (en) | 2015-06-03 | 2019-01-04 | 广东东阳光药业有限公司 | Substituted diethylenediamine compound and its application method and purposes |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4452808A (en) * | 1982-12-07 | 1984-06-05 | Smithkline Beckman Corporation | 4-Aminoalkyl-2(3H)-indolones |
| MX173362B (en) * | 1987-03-02 | 1994-02-23 | Pfizer | PIPERAZINIL HETERO-CYCLIC COMPOUNDS AND PROCEDURE FOR THE PREPARATION |
| FR2635104B1 (en) * | 1988-08-03 | 1992-04-30 | Synthelabo | INDOLONE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION |
| GB8830312D0 (en) * | 1988-12-28 | 1989-02-22 | Lundbeck & Co As H | Heterocyclic compounds |
| WO1998008816A1 (en) * | 1996-08-26 | 1998-03-05 | Meiji Seika Kaisha, Ltd. | Oxindole derivatives and psychotropic drugs |
| HUP0400953A3 (en) * | 2004-05-11 | 2008-02-28 | Egis Gyogyszergyar Nyilvanosan | Piperazine derivatives of alkyl-oxindoles, pharmaceutical compositions containing them, process for producing them and their use |
-
2004
- 2004-05-11 HU HU0400953A patent/HUP0400953A3/en unknown
-
2005
- 2005-05-11 EA EA200602084A patent/EA010789B1/en not_active IP Right Cessation
- 2005-05-11 AU AU2005240843A patent/AU2005240843B2/en not_active Expired - Fee Related
- 2005-05-11 CN CN2005800148934A patent/CN101010296B/en not_active Expired - Fee Related
- 2005-05-11 SI SI200530564T patent/SI1751105T1/en unknown
- 2005-05-11 NZ NZ551545A patent/NZ551545A/en unknown
- 2005-05-11 CZ CZ20060779A patent/CZ2006779A3/en unknown
- 2005-05-11 MX MXPA06013068A patent/MXPA06013068A/en active IP Right Grant
- 2005-05-11 DK DK05745440T patent/DK1751105T3/en active
- 2005-05-11 PL PL381615A patent/PL381615A1/en unknown
- 2005-05-11 SK SK5110-2006A patent/SK51102006A3/en not_active Application Discontinuation
- 2005-05-11 PL PL05745440T patent/PL1751105T3/en unknown
- 2005-05-11 ZA ZA200610345A patent/ZA200610345B/en unknown
- 2005-05-11 EP EP05745440A patent/EP1751105B1/en active Active
- 2005-05-11 DE DE602005010693T patent/DE602005010693D1/en active Active
- 2005-05-11 PT PT05745440T patent/PT1751105E/en unknown
- 2005-05-11 AT AT05745440T patent/ATE412633T1/en active
- 2005-05-11 RS RSP-2006/0621A patent/RS20060621A/en unknown
- 2005-05-11 UA UAA200613076A patent/UA84927C2/en unknown
- 2005-05-11 JP JP2007512357A patent/JP2007537227A/en not_active Ceased
- 2005-05-11 ES ES05745440T patent/ES2319795T3/en active Active
- 2005-05-11 US US11/596,465 patent/US7910591B2/en not_active Expired - Fee Related
- 2005-05-11 CA CA002566096A patent/CA2566096A1/en not_active Abandoned
- 2005-05-11 WO PCT/HU2005/000050 patent/WO2005108364A1/en active Application Filing
-
2006
- 2006-11-02 IL IL179028A patent/IL179028A/en not_active IP Right Cessation
- 2006-12-04 HR HR20060420A patent/HRP20060420A2/en not_active Application Discontinuation
- 2006-12-05 NO NO20065609A patent/NO20065609L/en not_active Application Discontinuation
- 2006-12-11 BG BG109769A patent/BG109769A/en unknown
Non-Patent Citations (1)
| Title |
|---|
| See references of WO2005108364A1 * |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20090306144A1 (en) | Pyridine derivatives of alkyl oxindoles as 5-ht7 receptor active agents | |
| AU2005240843B2 (en) | Piperazine derivatives of alkyl oxindoles | |
| KR20070011594A (en) | New piperazine derivatives of dialkyl oxindoles | |
| EP1751106B1 (en) | Piperazine derivatives of alkyl oxindoles | |
| JP2007537228A (en) | Indol-2-one derivatives for the treatment of diseases of the central nervous system, gastrointestinal system and circulatory system | |
| KR20070021252A (en) | Piperazine derivatives of alkyl oxindoles |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
| 17P | Request for examination filed |
Effective date: 20061207 |
|
| AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU MC NL PL PT RO SE SI SK TR |
|
| AX | Request for extension of the european patent |
Extension state: AL BA HR LV MK YU |
|
| 17Q | First examination report despatched |
Effective date: 20070924 |
|
| GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
| GRAS | Grant fee paid |
Free format text: ORIGINAL CODE: EPIDOSNIGR3 |
|
| GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
| AK | Designated contracting states |
Kind code of ref document: B1 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU MC NL PL PT RO SE SI SK TR |
|
| AX | Request for extension of the european patent |
Extension state: AL BA HR LV MK YU |
|
| REG | Reference to a national code |
Ref country code: GB Ref legal event code: FG4D |
|
| REG | Reference to a national code |
Ref country code: CH Ref legal event code: EP |
|
| REG | Reference to a national code |
Ref country code: IE Ref legal event code: FG4D |
|
| REF | Corresponds to: |
Ref document number: 602005010693 Country of ref document: DE Date of ref document: 20081211 Kind code of ref document: P |
|
| REG | Reference to a national code |
Ref country code: RO Ref legal event code: EPE |
|
| REG | Reference to a national code |
Ref country code: PT Ref legal event code: SC4A Free format text: AVAILABILITY OF NATIONAL TRANSLATION Effective date: 20090129 |
|
| REG | Reference to a national code |
Ref country code: GR Ref legal event code: EP Ref document number: 20090400254 Country of ref document: GR |
|
| REG | Reference to a national code |
Ref country code: SE Ref legal event code: TRGR |
|
| REG | Reference to a national code |
Ref country code: DK Ref legal event code: T3 |
|
| REG | Reference to a national code |
Ref country code: CH Ref legal event code: NV Representative=s name: PATENTANWAELTE SCHAAD, BALASS, MENZL & PARTNER AG |
|
| REG | Reference to a national code |
Ref country code: ES Ref legal event code: FG2A Ref document number: 2319795 Country of ref document: ES Kind code of ref document: T3 |
|
| REG | Reference to a national code |
Ref country code: HU Ref legal event code: AG4A Ref document number: E005173 Country of ref document: HU |
|
| REG | Reference to a national code |
Ref country code: PL Ref legal event code: T3 |
|
| PLBE | No opposition filed within time limit |
Free format text: ORIGINAL CODE: 0009261 |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT |
|
| 26N | No opposition filed |
Effective date: 20090730 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: MC Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20090531 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: LU Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20090511 |
|
| PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: FR Payment date: 20110523 Year of fee payment: 7 Ref country code: ES Payment date: 20110427 Year of fee payment: 7 Ref country code: TR Payment date: 20110427 Year of fee payment: 7 Ref country code: LT Payment date: 20110419 Year of fee payment: 7 Ref country code: GR Payment date: 20110420 Year of fee payment: 7 Ref country code: IE Payment date: 20110426 Year of fee payment: 7 Ref country code: SE Payment date: 20110525 Year of fee payment: 7 Ref country code: PT Payment date: 20110419 Year of fee payment: 7 Ref country code: IS Payment date: 20110426 Year of fee payment: 7 Ref country code: CZ Payment date: 20110420 Year of fee payment: 7 Ref country code: CH Payment date: 20110519 Year of fee payment: 7 |
|
| PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: HU Payment date: 20110506 Year of fee payment: 7 Ref country code: SI Payment date: 20110414 Year of fee payment: 7 Ref country code: NL Payment date: 20110601 Year of fee payment: 7 Ref country code: RO Payment date: 20110509 Year of fee payment: 7 Ref country code: SK Payment date: 20110420 Year of fee payment: 7 Ref country code: GB Payment date: 20110511 Year of fee payment: 7 Ref country code: PL Payment date: 20110413 Year of fee payment: 7 Ref country code: EE Payment date: 20110414 Year of fee payment: 7 Ref country code: DK Payment date: 20110512 Year of fee payment: 7 Ref country code: BG Payment date: 20110519 Year of fee payment: 7 Ref country code: FI Payment date: 20110526 Year of fee payment: 7 Ref country code: AT Payment date: 20110531 Year of fee payment: 7 Ref country code: BE Payment date: 20110428 Year of fee payment: 7 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: CY Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20081029 |
|
| PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: IT Payment date: 20110530 Year of fee payment: 7 Ref country code: DE Payment date: 20110510 Year of fee payment: 7 |
|
| REG | Reference to a national code |
Ref country code: PT Ref legal event code: MM4A Free format text: LAPSE DUE TO NON-PAYMENT OF FEES Effective date: 20121112 |
|
| BERE | Be: lapsed |
Owner name: EGIS GYOGYSZERGYAR NYRT Effective date: 20120531 |
|
| REG | Reference to a national code |
Ref country code: NL Ref legal event code: V1 Effective date: 20121201 |
|
| REG | Reference to a national code |
Ref country code: LT Ref legal event code: MM4D Effective date: 20120511 |
|
| REG | Reference to a national code |
Ref country code: CH Ref legal event code: PL |
|
| REG | Reference to a national code |
Ref country code: SE Ref legal event code: EUG |
|
| REG | Reference to a national code |
Ref country code: AT Ref legal event code: MM01 Ref document number: 412633 Country of ref document: AT Kind code of ref document: T Effective date: 20120511 |
|
| REG | Reference to a national code |
Ref country code: DK Ref legal event code: EBP |
|
| GBPC | Gb: european patent ceased through non-payment of renewal fee |
Effective date: 20120511 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SK Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20120511 Ref country code: FI Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20120511 Ref country code: LT Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20120511 Ref country code: EE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20120531 Ref country code: CH Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20120531 Ref country code: CZ Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20120511 Ref country code: IS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20121201 Ref country code: AT Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20120511 Ref country code: LI Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20120531 Ref country code: HU Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20120512 |
|
| REG | Reference to a national code |
Ref country code: SK Ref legal event code: MM4A Ref document number: E 5123 Country of ref document: SK Effective date: 20120511 |
|
| REG | Reference to a national code |
Ref country code: GR Ref legal event code: ML Ref document number: 20090400254 Country of ref document: GR Effective date: 20121204 |
|
| REG | Reference to a national code |
Ref country code: EE Ref legal event code: MM4A Ref document number: E003114 Country of ref document: EE Effective date: 20120531 |
|
| REG | Reference to a national code |
Ref country code: IE Ref legal event code: MM4A |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IT Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20120511 Ref country code: BE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20120531 Ref country code: PT Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20121112 Ref country code: GR Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20121204 Ref country code: SE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20120512 Ref country code: SI Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20120512 |
|
| REG | Reference to a national code |
Ref country code: SI Ref legal event code: KO00 Effective date: 20130103 |
|
| REG | Reference to a national code |
Ref country code: FR Ref legal event code: ST Effective date: 20130131 |
|
| REG | Reference to a national code |
Ref country code: DE Ref legal event code: R119 Ref document number: 602005010693 Country of ref document: DE Effective date: 20121201 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: NL Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20121201 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: DK Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20120531 Ref country code: GB Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20120511 Ref country code: FR Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20120531 Ref country code: IE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20120511 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: DE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20121201 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: BG Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20121231 |
|
| REG | Reference to a national code |
Ref country code: ES Ref legal event code: FD2A Effective date: 20130820 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: RO Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20120511 Ref country code: PL Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20120511 |
|
| REG | Reference to a national code |
Ref country code: PL Ref legal event code: LAPE |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: ES Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20120512 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: TR Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20120511 |